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The self-administration model is the primary non-clinical approach for assessing the reinforcing proper-
ties of novel compounds. Given the now frequent use of rats in self-administration studies, it is important
to understand the predictive validity of the rat self-administration model for use in abuse liability assess-
ments. This reviewof 71 drugs identiﬁes high concordance between ﬁndings from rat self-administration
studies and two clinical indicators of abuse liability, namely reports of positive subjective-effects andbuse potential
ependence
on-human primate
at
einforcement
cheduling
the DEA drug scheduling status. To understand the inﬂuence of species on concordance we compare
rodent and non-human primate (NHP) self-administration data. In the few instances where discrepan-
cies are observed between rat data and the clinical indicators of abuse liability, rat self-administration
data corresponds with NHP data in the majority of these cases. We discuss the inﬂuence of genetic fac-
tors (sex and strain), food deprivation state and the study design (acquisition or drug substitution) on
self-administration study outcomes and highlight opportunities to improve the predictive validity of theubjective-effects self-administration model.
© 2010 Elsevier Ltd. Open access under CC BY-NC-ND license.
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. Introduction
Understanding the abuse liability of novel compounds acting
n the central nervous system (CNS) is an important part of the
rug development process and is essential from a public health
erspective. Abuse liability is often deﬁned as the potential for
epeated taking of a drug for its reinforcing or subjective-effects,
r the avoidance of associated negative effects. A variety of factors
uch as the drug formulation, its ease of synthesis, cost and the
ocial acceptability of drug taking can also inﬂuence the likelihood
f abuse liability (Katz and Goldberg, 1988). The task of assessing
buse liability therefore requires a broad range of both clinical and
on-clinical models that can measure each of the distinct factors
hat contribute to risk of abuse. These models are referred to as
odels of abuse potential (O’Connor and Mead, 2010).
Non-clinical animal models of abuse potential, which include
rug self-administration, drug discrimination, physical depen-
ence and withdrawal and conditioned place preference, offer a
articularly valuable approach for predicting abuse liability (see
tor and Grifﬁths, 2003; Carter and Grifﬁths, 2009; Sanchis-Segura
nd Spanagel, 2006; Tzschentke, 1998 for review). Critically, these
odels can be used early on in the drug development process to
dentify candidate drugs that may offer a reduced risk of abuse
iability over clinically available therapies. Further, ﬁndings from
nimal models of abuse potential are required for the regulatory
pproval of centrally activedrugsand todetermine their scheduling
tatus, since these models permit testing of conditions not possible
r ethical inhumans (EMEA, 2006; FDA, 2010;HealthCanada, 2006;
pillane and McAllister, 2003). Given the importance of animal
odels of abuse potential for drug development, it is imperative
hat the predictive validity of each model for abuse liability is
nderstood. With this knowledge, the predicative limitations and
ey experimental variables of the models can be recognised and
pportunities to improve the predictive validity of the models can
e identiﬁed.
In the drug self-administration model, animals are required to
licit a response (such as a lever press) in order to obtain drug (Clark
t al., 1961; Weeks, 1962). This model is therefore used to examine
he reinforcing properties of a drug (that is, the ability of a drug
o increase the subsequent probability of a response that precedes
ts delivery), which is a key factor that inﬂuences the risk of abuse
iability (Balster and Bigelow, 2003; Johanson, 1990; Panlilio and
oldberg, 2007). Previous reviewers have found high predictive
alidity of the self-administration model for abuse liability when
onducted in non-human primates (NHPs) (Grifﬁths and Balster,
979; Johanson and Balster, 1978). In addition, experimental vari-
bles that can inﬂuence the outcome of NHP self-administration
tudies have been well described (Ator and Grifﬁths, 2003; Brady
nd Grifﬁths, 1976; Deneau et al., 1969; Schuster and Thompson,
and in assessments of abuse potential (for example, Haney and
Spealman, 2008). However, limited data is publically available con-
cerning the predictive validity of the self-administration model
conducted in rats for assessing abuse liability, even though the
choice of species used may be a key experimental variable that
inﬂuences the outcome of self-administration studies (Ator and
Grifﬁths, 2003; Schuster and Thompson, 1969). This review there-
fore provides an overview of ﬁndings from self-administration
studies conducted using rats in order to determine the predictive
validity of this model for understanding risk of abuse liability.
2. Methodological issues
A drugs propensity for abuse liability is dependent on a multi-
tude of social, economic and biological factors (Katz and Goldberg,
1988). Unsurprisingly, there exists no all-encompassing clinical
measure of ‘abuse liability’ and it must be considered as an abstract
term that can only be measured by the observation of more read-
ily identiﬁable endpoints. Nevertheless, in order to understand the
predictive validity of the rat self-administration model for abuse
liability, it is necessary to identify appropriate clinical indicators of
abuse liability againstwhich thepredictivevalidityof themodel can
be assessed. In the present review, two clinical indicators of abuse
liability are employed, namely reports of positive subjective-effects
(that is, reports of drug ‘liking’, ‘euphoria’ and/or ‘high’) measured
in controlled clinical studies, and the Drug Enforcement Agency
(DEA) drug scheduling status.
2.1. Clinical indicators of abuse liability
2.1.1. Reports of positive subjective-effects
The ﬁrst clinical indicator of abuse liability was chosen based
on its ability to measure drug reinforcement in humans. In theory,
this indicator would provide the most direct comparison to ﬁnd-
ings from non-clinical drug self-administration studies (Stephens
et al., 2010). Clinical studies considered to measure drug reinforce-
ment include those of subjective-effects, self-administration and
drug choice (Fischman, 1989; Henningﬁeld et al., 1991; Jasinski,
1977; Johanson and de Wit, 1989). In constructing this review,
studies of subjective-effectswere found to bemorewidely and con-
sistently used between different laboratories than either clinical
self-administration studies or studies of drug choice.
In studies of subjective-effects, human volunteers who have
typically had prior illicit drug experience (as recreational or drug
dependent users) are dosed with the test substance and record-
ings of subjective-effects are made at various intervals post-dosing
(see Carter and Grifﬁths, 2009 for further details). A number of
instruments have been used to measure subjective drug effects,
including the Visual Analogue Scales (VAS) of global drug effects,969; Woolverton and Nader, 1990).
In recent decades, methods for using rats in self-administration
tudies have been advanced (Caine et al., 1993) and rat self-
dministration studies arenowusedextensively for bothbasic drug
ddiction research (for example, Deroche-Gamonet et al., 2004)the Single Dose Questionnaire (Fraser et al., 1961) and the Addic-
tion Research Centre Inventory (Haertzen, 1966). These scales have
been reviewed extensively elsewhere (Fischman and Foltin, 1991;
Jaffe and Jaffe, 1989; Jasinski and Henningﬁeld, 1989). Essentially,
the scales address one or more of four key concepts:
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. Whether a subject feels a drug effect (drug feeling).
. Whether a subject can indicate the drug class most similar to the
test drug (drug class).
. Identiﬁcation of sensations the subject is experiencing (drug
symptoms).
. Whether the subject likes the drug (drug liking).
Reports of subjective-effects are generally recognised as being
ighly indicative of abuse liability (Grifﬁths et al., 2003; Jasinski,
977; Preston and Jasinski, 1991) and reports of ‘drug liking’
ave been found to correlate well with ﬁndings from NHP self-
dministration studies (Grifﬁths and Balster, 1979; Schuster and
hompson, 1969). For these reasons, reports of positive subjective-
ffects (that is, drug ‘liking’, ‘euphoria’ and/or ‘high’) were used
n the present review to address the predictive validity of the rat
elf-administration model for abuse liability.
.1.2. Drug scheduling status
In the United States of America, the process for drug scheduling
ypically requires the Food and Drug Administration (FDA) to com-
lete a medical and scientiﬁc assessment of the risk for abuse on
ehalf of the Department for Health and Human Services (HHS),
ncorporating input from the National Institute on Drug Abuse
NIDA), and to make a recommendation to the DEA for the appro-
riate scheduling status. The Controlled Substances Act (CSA) of
970 details the legislative control requirements for substances of
buse. According to the Act, substances may be placed into one
f ﬁve schedules (I–V) based upon the substance’s medical use,
otential for abuse and safety or dependence liability (see Spillane
nd McAllister, 2003 for review). Schedule I drugs are those with
ecognised abuse liability, but no currently accepted medical use
for example, lysergic acid diethylamide (LSD)), while substances
n schedules II–V are FDA approved compounds placed according
o their relative propensity for abuse or for the development of
hysical or psychological dependence. Thus, schedule III drugs are
onsidered to possess lower risk for abuse than schedule II drugs,
nd so on. To determine whether a substance should be scheduled,
nd if so, into which schedule it should be placed, the CSA details
n ‘eight factor analysis’ of abuse liability which considers:
. The drug’s actual or relative potential for abuse.
. Scientiﬁc evidence of the drug’s pharmacological effects.
. The state of current scientiﬁc knowledge regarding the sub-
stance.
. Its history and current pattern of abuse.
. The scope, duration, and signiﬁcance of abuse.
. What, if any, risk there is to the public health.
. The drug’s psychic or physiological dependence liability.
. Whether the substance is an immediate precursor of a substance
already controlled.
The broad scope of the eight-factor analysis suggested that
cheduling status could offer a more comprehensive indication
f ‘real-world’ abuse liability than reports of positive subjective-
ffects alone. Thus, drug scheduling status, obtained from the DEA
rug scheduling list of TheUnited StatesDepartment of Justice (U.S.
epartment of Justice, D.E.A., 2009) was included as the second
linical indicator of abuse liability.
.2. Categorisation of study ﬁndingsExperimental methodologies and reporting practices vary
onsiderably, not only between non-clinical self-administration
tudies and clinical studies of subjective-effects, but also within
he respective non-clinical and clinical literature.havioral Reviews 35 (2011) 912–938
In the animal drug self-administration literature, rates of
responding on an operant (for example, a lever) that leads to deliv-
ery of the test drug (termed the ‘active’ lever) are typically reported.
In most cases, a second operant is also present on which respond-
ing has no scheduled consequence (termed the ‘inactive lever’).
Whether a test drug maintains self-administration can therefore
be determined by the statistical comparison of group mean active
and inactive lever response rates, or between infusion rates main-
tained by various doses of the test drug and a negative control
(typically the vehicle of the test drug). Thus, the presence of self-
administration is identiﬁed as responding for the test drug which
signiﬁcantly exceeds responding for the negative control at one or
more doses of the test drug examined. In studieswhere no negative
control is included, self-administration is identiﬁed as responding
for the test drug which signiﬁcantly varies as a function of dose
and/or by responding selectively on the active lever over the inac-
tive lever. In some reports, individual animal data is reported, such
that the proportion of animals which self-administer the test drug
can be described.
Clinical studies employ a variety of rating scales to measure
positive subjective-effects (asdiscussed inSection2.1.1). Thus, sub-
jectsmay score on a continuous scale the extent towhich they ‘like’
the drug effect (for example, 0: dislike a lot; 50: neutral; and 100:
like a lot) and statistical comparisons are thenmadebetweengroup
mean rating scores following administration of the test drug and a
placebo control. In some studies, individual data are reported such
that the proportion of subjects who reported positive subjective-
effects can be described.
To facilitate the comparison of ﬁndings between and amongst
non-clinical and clinical studies in the present review, ﬁndings
from animal self-administration studies and clinical studies of
positive subjective-effects are classiﬁed as positive (+), equivo-
cal (+/−) or negative (−). Positive ﬁndings are deﬁned as those
in which statistically signiﬁcant reports of self-administration or
positive subjective-effects (that is, ‘drug liking’, ‘euphoria’ and/or
‘high’) were described or, for studies where individual data were
reported, where self-administration or positive subjective-effects
were reported in >50% of the experimental cohort. Equivocal
ﬁndings are deﬁned as those in which self-administration or pos-
itive subjective-effects were reported in at least one, but ≤50%
of the experimental cohort. Negative ﬁndings are deﬁned as
those in which no evidence of self-administration or positive
subjective-effects were found, as demonstrated by a lack of sta-
tistical signiﬁcance in group mean data, or the absence of positive
ﬁndings in any of the experimental cohort.
2.3. Inclusion and constraint criteria
A literature search using MEDLINE (1950-date), EMBASE (1974-
date), PUBMED, the Derwent Drug File (1983-date) and Biosis
Previews (1969-date) was performed to identify drugs that were
assessed in the rat self-administration model and which could be
comparedwith at least oneof the chosen clinical indicators of abuse
liability. For drugs that met this initial criterion, database searches
wereused to identify equivalent reports of self-administration con-
ducted inNHPs. By contrasting rodent andNHP self-administration
data, we sought to further understand the inﬂuence of species
in determining the predictive validity of the self-administration
model (see Section 4.1).
A number of additional inclusion and constraint criteria are
applied in order to provide a more useful and relevant database.
First, only self-administration studies that delivered drugs in
ways considered reﬂective of common clinical routes of admin-
istration (that is, intravenous, oral and inhalation) are included.
Second, studies where data from only one subject was reported are
excluded. Third, ﬁndings from studies that examined compounds
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n combination (for example, cocaine and heroin as a ‘speedball’, or
ashish) are excluded. Fourth, this review does not intend to offer
complete bibliography of rat self-administration studies. Thus,
or drugs where self-administration in rats has been extensively
eported (for example, cocaine and nicotine)we include only a rep-
esentative sample of studies that encompass a variety of study
esigns.
. The predictive validity of the rat self-administration
odel for abuse liability
The present review identiﬁed 71 drugs that were assessed in
he rat self-administration model and could be contrasted with
ndings from either clinical studies of subjective-effects and/or
rug scheduling status for thepurposeof understanding thepredic-
ive validity of the rat self-administration model for abuse liability
see summary tables; Tables 1–4). No published reports measuring
ubjective-effects were available for 17 drug cases and no evidence
f consideration for drug scheduling was available for ketocycla-
ocine.
Findings from rat self-administration studies were concordant
ith at least one clinical indicator of abuse liability in 64 of 71
90.1%) drug cases. That is, positive reports of self-administration
or a particular drug corresponded with either reports of positive
ubjective-effects and/or a drug scheduling status for the drug, and
ice-versa. When comparing ﬁndings from rat self-administration
tudies independentlywith each clinical indicator of abuse liability,
ndings from rat studies were concordant with reports of positive
ubjective-effects in 41 of 54 (75.9%) drug cases and were concor-
ant with drug scheduling status in 49 of 70 (70%) cases.
The following section summarizes the ﬁndings of this
eview, while a complete set of references is provided in
he summary tables. In addition to detailing whether drugs
ere self-administered in animals, produced reports of positive
ubjective-effects in humans and/or were listed as controlled
ubstances, the summary tables also detail the primary pharmaco-
ogical action of each drug, the strain of rat (or NHP species) used,
he class of training drug (if any) the animal was trained to self-
dminister prior to the test drug and the dominant drug experience
if any) of human volunteers used for studies of subjective-effects.
.1. Opioid drugs (Table 1)
Self-administration in rats was maintained by the -opioid
gonists codeine, diamorphine (heroin), dihydroetorphine, etoni-
azine, fentanyl, hydrocodone, levo-alphacetylmethadol (LAAM),
eperidine, methadone, morphine, oxycodone, propoxyphen,
emifentanil and sufentanil. These ﬁndings corresponded with
eports of positive subjective-effects in humans and/or recognised
cheduled status, typically schedule I–II (see Table 1 for references).
The atypical opioid analgesic tramadolwas self-administered in
ats (O’Connor and Mead, 2010) but is not a controlled substance
nd did not consistently engender reports of positive subjective-
ffects (Cami et al., 1994; Preston et al., 1991; Zacny, 2005). This
iscrepancy may be resolved, in part, by consideration of the com-
lex metabolic proﬁle of tramadol (see O’Connor and Mead, 2010
or discussion). Further, the use of a more complex reinforcement
chedule in rats and NHPs identiﬁed tramadol as a relatively weak
einforcer relative to typical analgesics with recognised abuse lia-
ility (O’Connor and Mead, 2010; Yanagita, 1978). These ﬁndings
re entirely consistent with the low risk of tramadol abuse liability
n humans (Epstein et al., 2006).
The-opioid antagonist levallorphan and thenon-selective opi-
id antagonist naloxone did not support self-administration in rats
Collins et al., 1984; Nishida et al., 1989). Although neither drug ishavioral Reviews 35 (2011) 912–938 915
scheduled, levallorphan did produce increases in ‘liking’ in human
volunteers, as measured using a single-dose opiate questionnaire.
However, overall changes in subjective-effects following levallor-
phan treatment were considered quite distinct from those of other
narcotic analgesics (Jasinski et al., 1967), highlighting a limitation
of using solely reports of positive subjective-effects as a clinical
indicator of abuse liability.
For drugs acting at both - and -opioid receptors, self-
administration in rats was reported for butorphanol, nalbuphine,
and pentazocine (Nishida et al., 1989; Steinfels et al., 1982). These
drugs also produced positive subjective-effects in humans (Mello
et al., 2005; Walsh et al., 2001; Zacny et al., 1997, 1998), but were
assigned with a lower scheduling status than the aforementioned
-agonists (typically schedule III–IV). The -partial agonist/-
antagonist nalorphine maintained self-administration in 1 out of
14 rats in one report (van Ree et al., 1978) but was later reported
to maintain robust self-administration in rats (Collins et al., 1984).
In humans, nalorphine produced reports of ‘liking’ (Jasinski et al.,
1967) and is a controlled substance (schedule III). Cyclazocine, a
-agonist/-antagonist, was not self-administered by rats (Collins
et al., 1984; Lahti and Collins, 1982) and is not listed as a controlled
substance. In clinical studies, subjects typically reported dyspho-
ric effects following cyclazocine administration, although a few
subjects (notably those with a preference for cocaine and/or hal-
lucinogens) reported positive subjective-effects (Haertzen, 1970;
Kumor et al., 1986). Finally, the - and -opioid receptor agonist
ketocyclazocine was self-administered in rats (Young and Khazan,
1983) while clinically, Kumor et al. (1986) reported that subjects
with a history of drug abuse generally demonstrated a strong dis-
like for ketocyclazocine. However, a subset of subjects did express
a liking for the drug, which similarly for cyclazocine, may reﬂect
their individual drug taking histories (Haertzen, 1970; Kumor et al.,
1986).
In summary, the current review identiﬁed 23 opioid related
drugs that had been assessed in the rat self-administration model
and which could be contrasted with reports of positive subjective-
effects in humans and/or drug scheduling status. The large volume
of literature on the self-administration of opioids in rats together
with the high concordance of ﬁndings between non-clinical studies
and the clinical endpoints of abuse liability provides strong sup-
port for the use of the rat model for assessing the abuse liability of
opioids.
3.2. Monoaminergic drugs (Table 2)
3.2.1. Dopaminergic drugs
Thirteen dopaminergic drugs were included in this review
whose function could broadly be categorised into inhibitors of
dopamine transporters (DAT), dopamine releasing agents or ago-
nists/antagonists at dopamine receptors.
Self-administration in rats was maintained by all DAT inhibitors
included in this review (bupropion, cocaine, methylphenidate
and nomifensine) and the dopamine reuptake inhibitor, phen-
metrazine. Of these drugs, only cocaine, methylphenidate and
phenmetrazine reliably produced reports of positive subjective-
effects in humans and are controlled substances (see Table 2 for
references). In contrast, bupropion and nomifensine do not pos-
sess signiﬁcant abuse liability, as conﬁrmed by clinical reports of
subjective-effects and their lack of scheduling status (Grifﬁth et al.,
1983;Hamilton et al., 1983;Miller andGrifﬁth, 1983; Taeuber et al.,
1979). The discrepancies between the non-clinical and clinical data
for bupropion and nomifensine are not yet fully understood, but
may reﬂect adverse events associatedwithhigh levels of drugexpo-
sure that limit the potential for abuse in humans, but which are not
relevant in theanimalmodel (seeSection5.2 for furtherdiscussion).
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Table 1
Summary of ﬁndings for opioid drugs.
Drug (synonym) Primary
pharma-
cology
Rat self-
administration
Non-Human Primate
Self-Administration
Reports of Positive
Subjective-Effects
Drug
Schedule
Status
Strain
(sex)
Acquisition
Study
Stimulant
Baseline
Opioid
Baseline
Other/
Unknown
Baseline
Reference Species
(sex)
Acquisition
Study
Stimulant
Baseline
Opioid
Baseline
Other/
Unknown
Baseline
Reference Non-Drug
Depen-
dent
Stimulant
Baseline
Opioid
Baseline
Other/
Unknown
Baseline
Reference
-opioid receptor drugs
Codeine
(Morphine
Methyl)
-Agonist WS(m) + (Nishida
et al.,
1989)
RH + (Woods
et al.,
1983)
+ (Kim
et al.,
2002)
II
BB(m) + (Lukas
et al.,
1986)
+/− (Walker
and
Zacny,
1998)
RH(m) + (Beardsley
and
Harris,
1997)
− (Zacny
et al.,
1996)
Diamorphine
(Heroin)
-Agonist WS(m) + (Madden
et al.,
1979)
RH(m) + (Beardsley
and
Harris,
1997)
+ (Comer
et al.,
1998)
I
LH(m) + (Alderson
et al.,
2000)
RH(m/f) + (Rowlett
et al.,
1998)
+ (Comer
et al.,
1999)
WS(m) + (Gerber
et al.,
1985)
WS(m) + (Ettenberg
et al.,
1982)
Dihydroetorphine
(DHE)
-Agonist WS(m) + (Wu
et al.,
1998)
RH(m) + (Beardsley
and
Harris,
1997)
ND II
FS(m) + (Martin
et al.,
1997)
Etonitazene -Agonist WS(m) + (Carroll
and Boe,
1982)
RH(m) + (Meisch,
1995)
ND I
LW(m) + (Suzuki
et al.,
1992)
FS(m) − (Suzuki
et al.,
1992)
Fentanyl -Agonist WS(m) + (Nishida
et al.,
1989)
RH(m/f) + (Ko et al.,
2002)
+ (Baylon
et al.,
2000)
II
FS(m) + (Martin
et al.,
1997)
RH(m/f) + (Broadbear
et al.,
2004)
Hydrocodone
(Dihy-
drocodeinone)
-Agonist WS(m) + (Tomkins
et al.,
1997)
ND + (Kaplan
et al.,
1997)
II/III
Levallorphan -Antagonist WS(m) − (Nishida
et al.,
1989)
RH(m/f) − (Aigner
and
Balster,
1979)
+ (Jasinski
et al.,
1967)
US
Levo-
alphacetylmethadol
(LAAM)
-Agonist SD(f) + (Young
et al.,
1979)
RH + (Harrigan
and
Downs,
1978)
ND II
AL(f) + (Moreton
et al.,
1976)
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Meperidine
(Pethidine)
-Agonist SD(f) + (Collins
et al.,
1984)
RH + (Yanagita
et al.,
1975a)
+ (Walker
and
Zacny,
1999)
II
Methadone -Agonist SD(m) + (Werner
et al.,
1976)
RH/PG + (Mello
et al.,
1988)
+ (Walsh
et al.,
1995)
II
AL(f) + (Moreton
et al.,
1976)
RH(m) + (Stewart
et al.,
1996)
+ (Comer
et al.,
2005)
Morphine -Agonist FS (m) + (Martin
et al.,
1997)
BB(m) + (Lukas
et al.,
1986)
+ (Zacny
and
Gutierrez,
2003)
II
WS(m) + (Nishida
et al.,
1989)
+ (Walker
and
Zacny,
1999)
LH(m) + (O’Connor
et al.,
2010)
+/- (Walker
and
Zacny,
1998)
Oxycodone -Agonist SD(m) + (Leri and
Burns,
2005)
ND + (Zacny
and
Gutierrez,
2003)
II
SD(m) + (Beardsley
et al.,
2004)
Propoxyphene
(Dextro-
propoxyphen)
-Agonist SD(f) + (Collins
et al.,
1984)
RH(m/f) + + (Hoffmeister
and
Schlichting,
1972)
ND II
Remifentanil -Agonist SD(m) + (Panlilio
and
Schindler,
2000)
RH(m/f) + (Ko et al.,
2002)
+ (Baylon
et al.,
2000)
II
LH(m) + (O’Connor
et al.,
2010)
Sufentanil -Agonist SD(m) + (Jaffe
et al.,
1989)
ND ND II
Tramadol -Agonist LH(m) + (O’Connor
et al.,
2010)
RH(m/f) + + (Yanagita
et al.,
1978)
− (Preston
et al.,
1991)
US
− (Cami
et al.,
1994)
+ (Zacny,
2005)
-/-opioid receptor drugs
Butorphanol -Agonist/-
Agonist
Antagonist
SD(f) + (Steinfels
et al.,
1982)
BB(m) + (Lukas
et al.,
1986)
+ (Walsh
et al.,
2001)
IV
− (Schlaepfer
et al.,
1998)
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Table 1 (Continued)
Drug (synonym) Primary
pharma-
cology
Rat self-
administration
Non-Human Primate
Self-Administration
Reports of Positive
Subjective-Effects
Drug
Schedule
Status
Strain
(sex)
Acquisition
Study
Stimulant
Baseline
Opioid Baseline Other/
Unknown
Baseline
Reference Species
(sex)
Acquisition
Study
Stimulant
Baseline
Opioid
Baseline
Other/
Unknown
Baseline
Reference Non-Drug
Depen-
dent
Stimulant
Baseline
Opioid
Baseline
Other/
Unknown
Baseline
Reference
Cyclazocine -Agonist/-
Antagonist
SD (f) − (Lahti and
Collins,
1982)
RH(m) − (Slifer
and
Balster,
1983)
+/− (Kumor
et al.,
1986)
US
SD (f) − (Collins
et al.,
1984)
− − (Young
and
Woods,
1981)
+/− (Haertzen,
1970)
Ketocyclazocine -Agonist/-
Agonist
SD(f) + (Young
and
Khazan,
1983)
RH − (Woods
et al.,
1979)
+/− (Kumor
et al.,
1986)
ND
Nalbuphine -Agonist/-
Partial
Agonist
SD (f) + (Steinfels
et al.,
1982)
RH + (Young
et al.,
1984)
+ (Mello
et al.,
2005)
US
BB(m) + (Lukas
et al.,
1986)
+ (Zacny
et al.,
1997)
Nalorphine -Partial
Agonist/-
Antagonist
WS(f) +/− (van Ree
et al.,
1978)
RH(m/f) +/− (Aigner
and
Balster,
1979)
+ (Jasinski
et al.,
1967)
III
SD(f) + (Collins
et al.,
1984)
+/− (Haertzen,
1970)
Naloxone Non-Selective
Antagonist
SD(f) − (Collins
et al.,
1984)
BB(m) − (Lukas
et al.,
1986)
− (Jasinski
et al.,
1967)
US
Pentazocine -Agonist/-
Partial
Agonist
WS/SD + (Nishida
et al.,
1989)
BB(m) + (Lukas
et al.,
1986)
+ (Zacny
et al.,
1998)
IV
SD(f) + (Steinfels
et al.,
1982)
RH + (Yanagita
et al.,
1975a)
Abbreviations for Tables 1–4: For rat strain: AL, Albino; FS, Fisher 344; HZ, Holtzman albino; LE, Long Evans; LH, Lister Hooded; LW, Lewis; SD, Sprague Dawley; SR, Sardinian; WS, Wistar. For NHP species: BB, Baboon; PG, Pigtail
Macaque; RH, Rhesus Macaque; SQ, Squirrel monkey. Other abbreviations: f, female; m, male; ND, no data; US, not scheduled. +, drug maintains self-administration in animals or reports of positive-subjective effect in humans;
+/−, drug maintains equivocal self-administration or reports of positive subjective effect; −, drug does not maintain self-administration or reports of positive subjective effect.
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Table 2
Summary of ﬁndings of monoaminergic drugs.
Drug (Synonym) Primary
Pharmacology
Strain
(sex)
Acquisition
Study
Stimulant
Baseline
Reference Species
(sex)
Acquisition
Study
Stimulant
Baseline
Opioid
Baseline
Other/
Unknown
Baseline
Reference Non Drug
Depen-
dent
Stimulant
Baseline
Opioid
Baseline
Depressant
Baseline
Other/
Unknown
Baseline
Reference Drug
Schedule
Status
Dopaminergic drugs
Apomorphine Mixed D-R
Agonist
SD(m) + (Yokel and Wise,
1978)
RH(m/f) + (Woolverton
et al.,
1984)
ND US
Bromocriptine Mixed D-R
Agonist
LE(m) + (Wise et al., 1990) RH(m/f) + (Woolverton
et al.,
1984)
− (Preston
et al.,
1992a)
US
Bupropion DAT Inhibitor SD(m) + (Tella et al., 1997) BB(m) + (Lamb
and
Grifﬁths,
1990)
− (Hamilton
et al.,
1983)
US
LH(m) + (O’Connor et al.,
2006)
SQ(m) + (Bergman
et al.,
1989)
+/− (Grifﬁth
et al.,
1983)
+/− (Miller
and
Grifﬁth,
1983)
Cathinone DA/NA
Releaser
LW(m) + (Gosnell et al.,
1996)
RH(m/f) + (Johanson
and
Schuster,
1981)
+ (Brenneisen
et al.,
1990)
I
Cocaine (Methyl
benzoylecgonine)
DAT
(NET/SERT)
Inhibitor
FS(m) + (Kosten et al., 1997) BB + (Grifﬁths
et al.,
1976)
+ (Foltin
and
Fischman,
1991)
II
LW(m) + (Kosten et al., 1997) SQ(m) + (Gerber
and
Stretch,
1975)
+ (Preston
et al.,
1992a)
WS(m) + (Carroll and Lac,
1997)
RH + (Corwin
et al.,
1987)
+ (Epstein
et al.,
1999)
Dextroamphetamine
(D-amphetamine)
DA (NA/5-HT)
Releaser
HZ(m) + (Pickens and Harris,
1968)
RH(m/f) + (Balster
and
Schuster,
1973)
+ (Zawertailo
et al.,
1995)
II
SD(m) + (Nielsen et al.,
1984)
BB + (Grifﬁths
et al.,
1976)
+ (Heishman
and
Henningﬁeld,
1991)
WS(f) + (van Ree et al.,
1978)
SQ(m) + (Gerber
and
Stretch,
1975)
+ (Jasinski
and
Preston,
1986)
Diethylpropion
(Diethylcathinone)
DA/NA/5-HT
Releaser
SD(m) + (Gotestam and
Andersson, 1975)
BB + (Grifﬁths
et al.,
1976)
+ (Jonsson
and
Sjoberg,
1967)
IV
RH(m/f) − (Weed
and
Woolverton,
1995)
+ (Jasinski
et al.,
1974)
Haloperidol D2 Antagonist SD(f) + (Glick and Cox,
1975)
RH − (Hoffmeister,
1977)
− (Wachtel
et al.,
2002)
US
SD(f) − (Collins et al., 1984)
Methylamphetamine
(Methamphetamine,
D-desoxyephedrine)
DA/NA/5-HT
Releaser
SD(m) + (Munzar et al.,
1999)
RH(m/f) + (Balster
and
Schuster,
1973)
+ (Johnson
et al.,
2005)
II
HZ(m) + + (Yokel and Pickens,
1973)
RH(m) + (Wang
and
Woolverton,
2007)
+ (Lamb
and
Henningﬁeld,
1994)
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Table 2 (Continued)
Drug (Synonym) Primary
Pharmacology
Strain
(sex)
Acquisition
Study
Stimulant
Baseline
Reference Species
(sex)
Acquisition
Study
Stimulant
Baseline
Opioid
Baseline
Other/
Unknown
Baseline
Reference Non Drug
Depen-
dent
Stimulant
Baseline
Opioid
Baseline
Depressant
Baseline
Other/
Unknown
Baseline
Reference Drug
Schedule
Status
Methylphenidate DAT Inhibitor
(DA/NA
releaser)
SD(m) + (Nielsen et al.,
1984)
RH(m) + + (Lile,
2006)
+ (Heishman
and
Henningﬁeld,
1991)
II
SQ(m) + (Bergman
et al.,
1989)
+ (Martin
et al.,
1971)
− (Heil
et al.,
2002)
Nomifensine DAT Inhibitor SD(m) + (Tella et al., 1997) BB(m) + (Lamb
and
Grifﬁths,
1990)
− (Taeuber
et al.,
1979)
US
WS(m) + + (Spyraki and
Fibiger, 1981)
SQ(m) + (Bergman
et al.,
1989)
− (Hamilton
et al.,
1983)
Phenmetrazine DA/NA Ago-
nist/Reuptake
inhibitor
SD(m) + (Gotestam and
Andersson, 1975)
RH + (Corwin
et al.,
1987)
+ (Chait
et al.,
1987)
II
BB + (Grifﬁths
et al.,
1976)
+ (W. R.
Martin
et al.,
1971)
Phentermine Mixed D-R
Agonist
WS(m) + (Papasava et al.,
1985)
BB + (Grifﬁths
et al.,
1976)
+ (Brauer
et al.,
1996)
IV
WS(m) − (Papasava et al.,
1985)
Adrenergic drugs
Clonidine 2-
adrenoceptor
agonist
LE + (Shearman et al.,
1981)
RH(m) + (Woolverton
et al.,
1982)
− (Cone
et al.,
1988)
US
BB(m) + (Weerts
and
Grifﬁths,
1999)
Ephedrine Adrenergic
agonist
SD(m) − (Briscoe et al., 1998) RH + (Anderson
et al.,
2001)
− (Chait,
1994)
US
SD + (Park et al., 2000) RH(m) + (Gold and
Balster,
1996)
+ (Martin
et al.,
1971)
Imipramine NET (SERT)
Inhibitor
SD(f) +/− (Collins et al., 1984) BB(m) − (Lamb
and
Grifﬁths,
1990)
− (Frewer
and
Lader,
1993)
US
Phenyl-
propanolamine
(PPA)
NE Agonist
and Reuptake
Inhibitor
SD(m) +/− (Wellman et al.,
1989)
RH(m/f) − (Woolverton
et al.,
1986)
− (Chait
et al.,
1987)
US
Serotonergic drugs
3,4-Methylenedioxy-
amphetamine (MDA)
5-HT releaser WS(m) + + (Markert and
Roberts, 1991)
BB + (Grifﬁths
et al.,
1976)
+ (Naranjo
et al.,
1967)
I
3,4-Methylenedioxy-
methamphetamine
(MDMA)
5-HT releaser LE(m) + + (Ratzenboeck et al.,
2001)
RH(m) + (Fantegrossi
et al.,
2004)
+ (Harris
et al.,
2002)
I
SD(m) + + (Schenk et al., 2003) RH(m) + (Wang
and
Woolverton,
2007)
+ (Cami
et al.,
2000)
BB + (Lamb
and
Grifﬁths,
1987)
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Fenﬂuramine 5HT-2B
agonist
SD(m) − (Gotestam and
Andersson, 1975)
BB − (Grifﬁths
et al.,
1976)
− (Brauer
et al.,
1996)
IV
WS(m) − (Papasava et al.,
1985)
− (Gotestam,
1979)
Mescaline 5HT-2A
agonist
ND + (Marvin Davis et al.,
1977)
RH(m) + (Fantegrossi
et al.,
2004)
ND I
RH − (Deneau
et al.,
1969)
Histaminergic drugs
Diphenhy-
dramine
H1 Antagonist WS(f) − (Fuchs and Coper,
1986)
SQ(m) + (Bergman
and
Spealman,
1986)
+/− (J.H Jaffe
et al.,
2004)
US
SD(m) +/− (Jun et al., 2004) BB(m) + (Sannerud
et al.,
1995)
+ (Mumford
et al.,
1996)
+/− (Preston
et al.,
1992b)
+/− (Wolf
et al.,
1989)
Tripelennamine H1 Antagonist WS(f) − (Fuchs and Coper,
1986)
RH(m) + (Beardsley
and
Balster,
1992)
− (Stern
et al.,
1989)
US
SQ(m) + (Bergman
and
Spealman,
1986)
+/− (Lange
and
Jasinski,
1986)
BB(m) + (Sannerud
et al.,
1995)
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Table 3
Summary of ﬁndings for GABAergic drugs.
Drug (synonym) Primary
pharmacology
Rat self-administration Non-Human Primate Self-Administration Reports of Postive Subjective Effect Drug
Schedule
Status
Strain
(sex)
Acquisition
Study
Stimulant
Baseline
Depressant
Baseline
Other/
Unknown
Baseline
Reference Species
(sex)
Acquisition
Study
Stimulant
Baseline
Depressant
Baseline
Other/
Unknown
Baseline
Reference Non drug
depen-
dent
Depressant
Baseline
Other/
Unknown
Baseline
Reference
Barbiturates
Amobarbital GABA-A
(Barbiturate)
SD(m) + (Richardson,
1970)
BB(m) + (Grifﬁths
et al.,
1981)
ND II
SD(m) − (Davis,
1968)
RH(m/f) + (Winger
et al.,
1975)
Hexobarbital GABA-A
(Barbiturate)
SD(m) − (Davis,
1968)
BB +/− (Grifﬁths
et al.,
1991)
ND III
Methohexital GABA-A
(Barbiturate)
HZ(m) + (Pickens
et al.,
1981)
BB(m) + (Grifﬁths
et al.,
1991)
ND IV
SD(f) + (Collins
et al.,
1984)
RH(m/f) + (Broadbear
et al.,
2005)
BB(m) + (Weerts
et al.,
1999)
Pentobarbital GABA-A
(Barbiturate)
LH(m) + (DeNoble
et al.,
1985)
RH(m/f) + (Vanover
et al.,
1989)
+ (Grifﬁths
et al.,
1979)
II
SD(f) + (Collins
et al.,
1984)
RH(m) + (Meisch
and
Lemaire,
1990)
− (Cole-
Harding
and de
Wit,
1992)
BB(m) + (Ator,
2002)
+ (McLeod
and
Grifﬁths,
1983)
RH(m/f) + (Winger
et al.,
1975)
+ (Sullivan
et al.,
1993)
RH(m/f) + (Yanigita
and
Takahashi,
1973)
Phenobarbital GABA-A
(Barbiturate)
WS(m) +/− (Yoshimura
et al.,
1984)
BB(m) +/− (Grifﬁths
et al.,
1991)
ND IV
SD(f) − (Collins
et al.,
1984)
Benzodiazepines
Chlordiazepoxide GABA-A (Ben-
zodiazepine)
SD(m) + (Davis
et al.,
1987)
BB(m) +/− (Ator,
2002)
ND IV
HZ(m) − + (Falk and
Tang,
1989a)
RH(m/f) + (Yanigita
and
Takahashi,
1973)
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Diazepam GABA-A (Ben-
zodiazepine)
LE/SD +/− (Oittinen
et al.,
2001)
RH(m) + (Gomez
et al.,
2002)
+/− (Roache
and
Grifﬁths,
1989)
IV
SD(f) − (Collins
et al.,
1984)
BB(m) +/− (Grifﬁths
et al.,
1981)
+ (Grifﬁths
et al.,
1979)
LE(m) + (Pilotto
et al.,
1984)
RH(m/f) +/− (Grant
and
Johanson,
1987)
+/− + (Singh
et al.,
2001)
SD(m) + (Naruse
and
Asami,
1990)
RH(m/f) + (Yanigita
and
Takahashi,
1973)
+ (de Wit
et al.,
1989)
RH(m/f) + (Bergman
and
Johanson,
1985)
Flurazepam GABA-A (Ben-
zodiazepine)
SD(f) + (Collins
et al.,
1984)
RH(m/f) + (Johanson,
1987)
− (de Wit
et al.,
1984)
IV
HZ(m) − (Falk and
Tang,
1989b)
BB(m) +/− (Grifﬁths
et al.,
1981)
RH(m/f) + (Johanson
and
Schuster,
1986)
Medazepam GABA-A (Ben-
zodiazepine)
SD (f) + (Gotestam,
1973)
BB(m) +/− (Grifﬁths
et al.,
1981)
ND IV
Midazolam GABA-A (Ben-
zodiazepine)
LE(m) + (Szostak
et al.,
1987)
SQ(m) + (Munzar
et al.,
2001)
ND IV
LE(m) + (Finlay
et al.,
1989)
RH(m/f) + (Broadbear
et al.,
2005)
RH(m) + (Stewart
et al.,
1994)
GABAergic drugs with poorly deﬁned mechanisms
Gamma-
Hydroxybutyric
Acid (GHB)
GABA-B/GHB-
receptor
SR (m) + (Colombo
et al.,
1998)
RH + (Woolverton
et al.,
1999)
+ (Carter
et al.,
2006)
I–III
WS(m) + (Colombo
et al.,
1995)
RH(m/f) − (Beardsley
et al.,
1996)
− (Ferrara
et al.,
1999)
Propofol GABA-A
(other/unknown)
WS(m) + (LeSage
et al.,
2000)
BB(m) + (Weerts
et al.,
1999)
+/− (Zacny
et al.,
1993)
US
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Table 4
Summary of ﬁndings for cholinergic, cannabinoid, glutamatergic and adenosinergic drugs, steroids and drugs with mixed or poorly deﬁned mechanisms.
Drug (synonym) Primary
pharmacology
Rat self-administration Non-Human Primate Self-Administration Reports of Positive Subjective-Effects Drug
Schedule
StatusStrain
(sex)
Acquisition
Study
Stimulant
Baseline
Other/
Unknown
Baseline
Reference Species
(sex)
Acquisition
Study
Stimulant
Baseline
Opioid
Baseline
Depressant
Baseline
Other/
Unknown
Baseline
Reference Non Drug
Depen-
dent
Stimulant
Baseline
Depressant
Baseline
Other/
Unknown
Baseline
Reference
Cholinerigc drugs
Nicotine nAChR
Receptor
Agonist
LE(m) + (Corrigall
and Coen,
1989)
SQ(m) + (Le Foll
et al.,
2007)
+ (Henningﬁeld
et al., 1985)
US
SD(m) + (Tessari
et al.,
1995)
SQ(m) + (Goldberg
et al.,
1981)
− (Heishman
et al., 1993)
SD(m) + (Donny
et al.,
1997)
SQ(m) + (Sannerud
et al.,
1994)
− + (Soria et al.,
1996)
LE(m) + (DeNoble
and Mele,
2006)
BB(m) +/− (Ator and
Grifﬁths,
1983)
LH(m) + (O’Connor
et al.,
2009)
RH(m) + (Slifer
and
Balster,
1985)
Scopolamine mAChR
Antagonist
SD(f) + (Glick,
1982)
RH(m) +/− (Ranaldi
and
Woolverton,
2002)
ND US
Varenicline 42 nAChR
Partial Agonist
LE(m) + (Rollema
et al.,
2007)
ND + − McColl et al.,
2008
US
Cannabinoid drugs
9-Tetrahydro-
cannabinol (THC)
CB 1/2
Receptor
Agonist
WS(m) + (Takahashi
and
Singer,
1979)
RH(m) − (Mansbach
et al.,
1994)
+ (Kelly et al.,
1994)
I
RH − − − (R. T.
Harris
et al.,
1974)
+ (Lukas et al.,
1995)
SQ(m) + (Justinova
et al.,
2003)
SQ + (Tanda
et al.,
2000)
Glutamatergic drugs
1-[1-(2-
Thienyl)cyclohexyl]
pyrrolidine (TCPy)
NMDA
Antagonist
SD(f) + (Marquis
and
Moreton,
1987)
BB(m) + (Lukas
et al.,
1984)
ND I
Dextromethorphan NMDA
Antagonist
(non-
competitive at
34 nAChR)
SD(m) − (Jun et al.,
2004)
RH(m/f) + (Nicholson
et al.,
1999)
+ (Ziaee et al.,
2005)
US
RH(m/f) + (Yanagita
et al.,
1975b)
Ketamine NMDA
Antagonist
FS(m) + (Rocha
et al.,
1996)
RH(m) + (Moreton
et al.,
1977)
+ (Bowdle et al.,
1998)
III
SD(f) + (Marquis
and
Moreton,
1987)
RH(m) + + (Young
and
Woods,
1981)
+ (Morgan et al.,
2004)
SD(f) + (Collins
et al.,
1984)
BB(m) + (Lukas
et al.,
1984)
RH + (Carroll
and Stotz,
1983)
E.C.O
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Phencylcidine (PCP) NMDA
Antagonist
SD(f) + (Marquis
et al.,
1989)
BB(m) + (Lukas
et al.,
1984)
+ (Fauman and
Fauman, 1980)
II
WS(m) + (Carroll
et al.,
1981)
RH(m) + (Aigner
and
Balster,
1979)
SD(f) + (Collins
et al.,
1984)
RH(m) − + (Young
and
Woods,
1981)
RH(f) + (Carroll
et al.,
2000)
RH(m) +/− (Carroll
et al.,
2000)
Adenosinergic drugs
Caffeine Adenosine
Receptor
Antagonist
SD(m) − (Briscoe
et al.,
1998)
RH(m/f) − (Hoffmeister
and
Wuttke,
1973)
+ (Grifﬁths et al.,
1989)
US
SD(f) +/− (Atkinson
and
Enslen,
1976)
RH +/− (Sekita
et al.,
1992)
+ (Childs and de
Wit, 2006)
SD(f) +/− (Collins
et al.,
1984)
RH(m) +/− (Deneau
et al.,
1969)
+ (Garrett and
Grifﬁths, 2001)
Steroids
Testosterone Androgen
Receptor
activation
SD(m) + (Wood
et al.,
2004)
ND − (Fingerhood
et al., 1997)
III
Drugs with mixed or
poorly deﬁned
mechanisms
Chlorpromazine Anti Psychotic SD(f) − (Collins
et al.,
1984)
RH − (Deneau
et al.,
1969)
ND US
RH(m/f) − (Aigner
and
Balster,
1979)
RH(m/f) − (Hoffmeister
and
Goldberg,
1973)
Ethanol CNS
Depressent
LE(m) + (Grant
and
Samson,
1985)
RH(m/f) + (Williams
et al.,
2004)
+ (Mintzer et al.,
1997)
US
SD(m) + (Lyness
and
Smith,
1992)
Modaﬁnil A-typical
Stimulant
SD(m) − (Deroche-
Gamonet
et al.,
2002)
RH(m) + (Gold and
Balster,
1996)
+ (Jasinski,
2000)
IV
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Of the remaining eight dopaminergic drugs, self-administration
n rats was maintained by the dopamine releasers d-amphetamine,
iethypropion, cathinone and methylamphetamine, which cor-
esponded with reports of positive subjective-effects in humans
nd scheduling status (schedule I–IV; see Table 2 for references).
he mixed dopamine receptor agonists apomorphine, bromocrip-
ine were self-administered in rats (Wise et al., 1990; Yokel and
ise, 1978) but bromocriptine did not produce reports of positive
ubjective-effects in human participants (Preston et al., 1992a) and
either drug is listed as a controlled substance. These discrepan-
ies may reﬂect negative side effects associated with apomorphine
nd bromocriptine use in humans, thus limiting their potential
or abuse (see Section 5.2 for discussion). Interestingly, the mixed
opamine receptor agonist phentermine was self-administered
n rats, but only under conditions of food deprivation (Papasava
t al., 1985). Clinically, phentermine produced reports of positive
ubjective-effects (Brauer et al., 1996) and is listed as a controlled
ubstance. Finally, the dopamine receptor antagonist haloperidol
upported the acquisition of self-administration in drug-naïve rats
Glick and Cox, 1975). This report is surprising given the lack of
aloperidol abuse liability, and contrasts with a later negative ﬁnd-
ng reported in rats under similar experimental conditions (Collins
t al., 1984), suggesting that further studies are required to fully
nderstand the behavioural effects of haloperidol in the rat self-
dministration model.
.2.2. Adrenergic drugs
The noradrenergic transporter (NET) inhibitor imipramine
nd the NET inhibitor/noradrenergic receptor agonist phenyl-
ropanolamine produced only equivocal reports of self-
dministration in rodents (Collins et al., 1984; Wellman et al.,
989). These drugs did not engender reports of positive subjective-
ffects in human participants (Chait et al., 1987; Frewer and Lader,
993) and are not listed as controlled substances.
In contrast to ﬁndings for NET inhibitors, the adrenergic
eceptor agonists clonidine and ephedrine readily supported the
cquisition of self-administration in drug-naïve rats (Park et al.,
000; Shearman et al., 1981), although ephedrine was not self-
dministered by rats trained to self-administer cocaine (Briscoe
t al., 1998). Both clonidine and ephedrine did not consistently pro-
uce reports of positive subjective-effects in humans (Chait, 1994;
one et al., 1988; Martin et al., 1971) and neither drug is listed as a
ontrolled substance.
.2.3. Serotonergic drugs
The serotonin (5-HT) releasers 3,4-methylenedioxyamphet-
mine (MDA) and 3,4-methylenedioxymethamphetamine
MDMA), and the 5HT-2A agonist mescaline supported self-
dministration in rats and produced reports of positive
ubjective-effects in humans (see Table 2 for references). Both
DA andMDMAare controlled substances (schedule I). In contrast,
he 5HT-2B agonist fenﬂuramine was not self-administered in rats
Gotestam and Andersson, 1975; Papasava et al., 1985) and did not
roduce reports of positive subjective-effects (Brauer et al., 1996;
otestam, 1979). Fenﬂuramine is listed as a controlled substance
schedule IV), but thismay reﬂect signiﬁcant side effects associated
ith withdrawal from fenﬂuramine use (Vivero et al., 1998).
.2.4. Histaminergic drugs
Of the two histamine (H)1 receptor antagonists included in this
eview, tripelennamine was not self-administered in rats (Fuchs
nd Coper, 1986) and is an unscheduled substance that engendered
nly equivocal reports of positive subjective-effects in human vol-
nteers (Lange and Jasinski, 1986). Diphenhydramine supported
imited self-administration in rats when delivered intravenously
Jun et al., 2004), but was not self-administered when rats werehavioral Reviews 35 (2011) 912–938
given theopportunity todrinka solution containing thedrug (Fuchs
and Coper, 1986). These reports highlight the important inﬂuence
of the drug administration route on self-administration study out-
comes (see also Ator and Grifﬁths, 2003; Schuster and Thompson,
1969; Woolverton and Nader, 1990). Diphenhydramine is not
a controlled substance, although reports of positive subjective-
effects have been recorded (Jaffe et al., 2004; Mumford et al., 1996;
Preston et al., 1992b; Wolf et al., 1989).
In summary, the present review captured ﬁndings from 23
monoaminergic related drugs. While the overall concordance
between ﬁndings from non-clinical studies and the clinical indica-
tors of abuse liability was high, clear discrepancies were observed
for certain mixed dopamine receptor agonists (apomorphine and
bromocriptine) and DAT inhibitors (bupropion and nomifensine),
with false-positive ﬁndings observed in animals for all four drugs
suggesting a potential over-sensitivity of this model. The adren-
ergic drugs tended to produce equivocal ﬁndings across the rat
self-administration literature, but were largely devoid of abuse lia-
bility based solely on the two clinical endpoints used in our current
review (but see Martin et al., 1971). Further studies are required
to understand these discrepancies, which may point to important
predictive limitations of the self-administration model for abuse
liability and/or the need to apply more advanced analysis of the
drugs effects in order to improve the predictive validity of the
model (for further discussion see Section 5).
3.3. GABAergic drugs (Table 3)
Of the 12 GABAergic related drugs included in this review, 11
are listed as controlled substances (schedules II–IV; see Table 3).
The sole exception is the anaesthetic agent propofol, which main-
tained self-administration in rats (LeSage et al., 2000) but produced
only limited reports of positive subjective-effects in humans (Zacny
et al., 1993). However, recent reviewers have called for regulation
of propofol as a controlled substance due to accumulating evidence
demonstrating clinical abuse of this drug (Wilson et al., 2010).
Of the barbiturate drugs, amobarbital, methohexital and pento-
barbital were self-administered in rats (Collins et al., 1984; Davis,
1968; DeNoble et al., 1985; Pickens et al., 1981; Richardson, 1970),
while phenobarbital self-administration in rats was at best equivo-
cal (Collinset al., 1984;Yoshimuraet al., 1984). The schedule III drug
hexobarbital did not support the acquisition of self-administration
in drug-naïve rats (Davis, 1968), however it was self-administered
in rats under conditions of unavoidable shock. This study pro-
vided early evidence that stress can inﬂuence the outcome of
self-administration studies (see alsoPilotto et al., 1984;Richardson,
1970).
Of the benzodiazepine drugs, chlordiazepoxide, diazepam, ﬂu-
razepamandmidazolamwere self-administered in rats. Diazepam,
but not ﬂurazepam, produced reports of positive subjective-
effects when examined in humans (see Table 3 for references).
Falk and Tang (1989a) reported that chlordiazepoxide maintained
self-administration in rats that had previously been trained to
self-administer ethanol, but was not self-administered in cocaine
trained rats, highlighting the importance of the study design in
determining study outcome (see Section 4.4 for further discussion).
Gamma-hydroxybutyric acid (GHB), a metabolite of GABA
that shows commonality with the behavioural effects of ethanol
(Nicholson and Balster, 2001), maintained self-administration in
rats (Colombo et al., 1995, 1998) and produced reports of positive
subjective-effects in experienced drug users, but not in non-drug
dependent individuals (Carter et al., 2006; Ferrara et al., 1999).
In summary, the overall agreement between ﬁndings from rat
studies and theclinical indicatorsof abuse liability lends support for
theuse of the ratmodel in assessing the abuse liability ofGABAergic
drugs. To someextent, this conclusion is hamperedby the relatively
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ew published reports using rodents to examine the reinforcing
roperties of certain GABAergic drugs. The routine use of rodents
or the self-administration of drugs in this class is likely to require
urther optimization of methodological variables. In particular, the
nimal’s drug history (see Section 4.4 for further discussion) is
ecognised as an important factor contributing to the reinforcing
ffects of benzodiazepines (Grifﬁths and Weerts, 1997; Licata and
owlett, 2008).
.4. Cholinergic drugs (Table 4)
The nicotinic-acetylcholinergic receptor agonist nicotine main-
ained reliable self-administration in rats. In humans, the ability of
icotine administration to produce reports of positive subjective-
ffects depended greatly upon the previous drug experience
f participants (Soria et al., 1996 see Table 4 for references).
lthough abuse of nicotine is widely acknowledged, it is not
isted as a controlled substance. The muscarinic-acetylcholinergic
eceptor antagonist scopolamine and the alpha4beta2 nicotinic
cetylcholine receptor partial agonist varenicline were both self-
dministered in rats (Glick, 1982; Rollema et al., 2007). In
on-smoking individuals, varenicline produced a drug high, but
his report corresponded with the mean peak report of nausea
nd was therefore considered unlikely to reﬂect a positive expe-
ience (McColl et al., 2008). Varenicline and scopolamine are not
ontrolled substances.
While a number of other nicotinic compounds have been
ssessed in the rat self-administration model, including isoare-
olone (Shoaib, 2006), 5-iodo-A-85380 (Liu et al., 2003) and
obelline (Harrod et al., 2003), these ﬁndings could not be included
n the present review due the absence of any comparable clinical
ata. To fully understand the predictive validity of the rat model
or this drug class, it will be of great value to examine the abuse
otential of these and other cholinergic related drugs in humans.
In summary, results from the limited database of cholinergic
rugs in the rat self-administration model show good concordance
ith clinical subjective-effects, though relatively poor concordance
ith drug scheduling status. This is likely due to the fairly unique
istory of nicotine use and abuse, and its subsequent classiﬁcation
s an unscheduled compound.
.5. Cannabinoid drugs (Table 4)
Self-administration of 9-tetrahydrocannabinol (THC) was
eported in rats, but only when animals were food deprived
nd a ﬁxed-time 1-min non-contingent food delivery schedule
as present (Takahashi and Singer, 1979) (see also Takahashi
nd Singer, 1980). Clinically, THC produced reports of positive
ubjective-effects in humans (Kelly et al., 1994; Lukas et al., 1995)
nd THC is a controlled substance (schedule I).
Demonstrating self-administration of THC has proven a difﬁ-
ult task in both rats and NHPs and it is clear that experimental
arameters including strain, motivational state, dose and injection
peedare critical determinants of success (for thorough reviews see
anagis et al., 2008; Tanda and Goldberg, 2003). Using a two-bottle
hoice paradigm in rats, consumption of a solution containing
ashish (the major psychoactive constituent of which being THC)
as reported to be highly variable in rats (Corcoran and Amit,
974). The most convincing evidence of THC self-administration in
nimals to date has been reported in squirrel monkeys (Justinova
t al., 2003; Tandaet al., 2000). The failure of THC tomaintain robust
elf-administration is likely due to the delayed onset and slow
etabolism of THC, but may also simply reﬂect the relatively weak
einforcing effects of this drug (Maldonado, 2002). In rats, self-
dministration of the synthetic CB1 receptor agonist WIN 55,212-2
as proven more robust (Fattore et al., 2001; Lecca et al., 2006), buthavioral Reviews 35 (2011) 912–938 927
further studiesusing clinically available cannabinoids (for example,
nabilone) would be advantageous to fully understand the utility of
the rat self-administration model for assessing the abuse liability
of drugs in this class.
3.6. Glutamatergic drugs (Table 4)
The NMDA antagonists 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine
(TCPy), ketamine and phencylcidine (PCP) were self-administered
in rats and are controlled substances (schedule I–III) that, when
examined in human subjects, produced reports of positive
subjective-effects (see Table 4 for references). The mixed-
action glutamatergic related drug dextromethorphan was not
self-administered in rats, except for when administered in combi-
nation with the anti-histamine diphenhydramine (Jun et al., 2004).
Although dextromethorphan is not listed as a controlled substance,
it produced reports of positive subjective-effects in humans (Ziaee
et al., 2005). Further, clinical abuse of dextromethorphan for
its dissociative effects has been recognised (Mutschler et al.,
2010; Romanelli and Smith, 2009). Collectively, ﬁndings from rat
self-administration studies using glutamatergic drugs show broad
agreementwith the clinical indicators of abuse liability, supporting
the use of the rat model for assessing the abuse liability of drugs
in this class.
3.7. Adenosinergic drugs (Table 4)
The adenosine receptor antagonist caffeine supported only
low levels of self-administration in rats and is not a con-
trolled substance. Caffeine reliably produced reports of positive
subjective-effects in human volunteers (see Table 4 for references).
Clearly, further studies using clinically available adenosinergic
drugs (for example, 8-chlorotheophylline) will be of value to thor-
oughly assess the utility of the self-administration model in abuse
liability assessments for drugs in this class.
3.8. Steroids (Table 4)
The anabolic-androgenic steroid (AAS) testosterone maintained
self-administration in rats (Wood et al., 2004) but did not produce
reports of positive subjective-effects in humans (Fingerhood et al.,
1997). Testosterone is a controlled substance (schedule III). The
abuse liability of testosterone and other AAS drugs is thought to be
inﬂuenced by a combination of factors that include psychological
dependence due to body image disorders, avoidance of hypogo-
nadism experienced during withdrawal, but also hedonic effects
associated with AAS use (Kanayama et al., 2010). Further studies
are required to fullyunderstand thevalueof the self-administration
model in abuse liability assessments of steroids.
3.9. Other mechanisms (Table 4)
The antipsychotic chlorpromazine was not self-administered
in rats (Collins et al., 1984) and is not a controlled substance.
Ethanol maintained self-administration in rats (Grant and Samson,
1985; Lyness and Smith, 1992) and engendered reports of positive
subjective-effects (Mintzer et al., 1997). Although abuse of ethanol
is widely acknowledged, it is not listed as a controlled substance.
Finally, the anti-narcoleptic and pro-cognitive agent modaﬁnil
did not support self-administration in drug-naïve rats (Gold and
Balster, 1996). However, modaﬁnil produced reports of positive
subjective-effects in humans (Jasinski, 2000) and is a controlled
substance (schedule IV). Reviewers have commented that the lack
ofwidespreadmodaﬁnil abuse is likely a consequence of its limited
solubility in water and chemical instability at high temperatures,
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hus restricting its potential for abuse via intravenous injection and
moking, respectively (Jasinski and Kovacevic-Ristanovic, 2000).
. Recognising key variables that inﬂuence study outcomes
Identifying and understanding discrepancies between non-
linical studies and their clinical counterparts is a critical step
or determining the predictive strengths and limitations of a non-
linical model. Moreover, such discrepancies may point to ways of
mproving the predictive validity of a model. Of the 71 drug cases
ncluded in this review, a number of discrepancies were identiﬁed
etween ﬁndings from rat self-administration studies and one or
oth clinical indicators of abuse liability (see Table 5 for summary).
To identify discrepancies, we ﬁrst classiﬁed non-clinical or
linical data sets for a particular drug as representing an over-
ll positive signal when ﬁndings from at least one study in the
espective data setswere initially categorised as ‘equivocal’ or ‘pos-
tive’ (for example, rat self-administration data sets for imipramine
nd ﬂurazepam, and clinical studies for ketocyclazocine and nico-
ine were all classiﬁed as positive signals). Where no reports
f self-administration or positive subjective-effects were found
or a particular drug, the respective data set was classiﬁed as
epresenting an overall negative signal (for example, the rat self-
dministration data set for cyclazocine and the clinical data set
or fenﬂuramaine were both classiﬁed as negative signals). Non-
linical and clinical data set classiﬁcations were then compared for
ach drug and discrepancies categorised into those representing
alse positives (that is, a positive signal from self-administration
tudies in rats but a negative signal from studies of positive
ubjective-effects and/or scheduling status – a Type I error) or false
egatives (that is, a lack of self-administration in rats, but a pos-
tive signal from studies of subjective-effects and/or scheduling
tatus – a Type II error). In taking this approach, seven drug cases
ere identiﬁed where ﬁndings from rodent studies were consid-
red at odds with both reports of positive subjective-effects and
he drug scheduling status (see Table 5, ‘Both clinical endpoints’).
further six cases were identiﬁed where rat data were at variance
nly with reports of positive subjective-effects (see Table 5, ‘Pos-
tive subjective-effects only’), and 14 cases were identiﬁed where
at data were at variance only with the drug scheduling status (see
able 5, ‘Drug scheduling status only’).
In the following sections we further consider these discrepan-
ies in the context of recognising key variables that can inﬂuence
he outcome of self-administration studies and identifying poten-
ial areas of research that may improve the predictive validity
f the self-administration model. It must be recognised that for
ome discrepancies, limited published data precludes conclusive
xplanations being made and, at best, we can only speculate as to
he underlying reasons. Secondly, large variation in the method-
logies between studies included in our current review prohibits
more in-depth analysis of the contribution of certain variables
such as rat strain, sex or food deprivation state) to the outcome of
elf-administration studies. In these instances, we highlight where
urther empirical studies or speciﬁcally designed meta-analyses
ould be valuable to fully understand the inﬂuence of such fac-
ors on the predictive validity of the rat self-administration model
or abuse liability.
.1. Species differences
Previous reviewers of the self-administration model have sug-
ested that the species used may be a key experimental variable
hat inﬂuences the outcome of studies (Ator and Grifﬁths, 2003;
chuster and Thompson, 1969). In particular, rodent abuse poten-
ial models have been considered useful but not sufﬁcient for
redicting abuse liability, since species differences in metabolichavioral Reviews 35 (2011) 912–938
and receptor proﬁles, for example, may result in misleading con-
clusions regarding the abuse liability of some compounds (Epstein
et al., 2006). Since ﬁndings from NHP studies are considered
by some to more closely reﬂect the human potential for abuse
than any other species (Ator and Grifﬁths, 2003; Mansbach et al.,
2003; Weerts et al., 2007), we contrasted ﬁndings from rat self-
administration studies with NHP studies to further understand the
inﬂuence of species differences on the predictive validity of the
self-administration model. Of the 71 drugs included in this review,
ﬁndings from self-administration studies conducted in NHPs were
available for comparison for all but ﬁve drugs (hydrocodone, oxy-
codone, sufentanil, varenicline and testosterone; see Tables 1–4 for
ﬁndings from NHP studies).
A comparison of discrepancies between rat studies and the
clinical endpoints of abuse liability with discrepancies observed
between NHP studies and the same clinical endpoints (see Table 5)
revealed only ﬁve discrepant drug cases that could be considered
as ‘unique’ to rodent studies (that is, rat self-administration studies
did not predict abuse liability, butNHP studies did). Theseﬁve cases
were haloperidol, imipramine, modaﬁnil, phenylpropanolamine
and hexobarbital. Considering the limited published data available
for these cases, further research is required to understand whether
these discrepancies truly reﬂect speciﬁc limitations of the rat for
understanding abuse liability (that is, limitations due to species dif-
ferences). It may be that experimental variables (for examples, see
Sections4.2–4.4)werenotoptimised for twoof thediscrepant cases
categorised as false negatives (modaﬁnil and hexobarbital), while
the remaining three cases categorised as false positives included rat
self-administration ﬁndings that were either conﬂicting (haloperi-
dol) or ‘equivocal’ (imipramine, phenylpropanolamine), pointing to
limited reinforcing effects of these drugs in the rat model.
The overall similarity between ﬁndings from rat and NHP stud-
ies identiﬁed in the current review is perhaps unsurprising, given
evidence that the principal mammalian brain pathways involved
in mediating the reinforcing effects of abused drugs are conserved
across mammalian species (Panksepp et al., 2002). Nevertheless,
in the design of non-clinical self-administration studies, species
choice should be given careful consideration. For example, where
there are clear species differences in target pharmacology, and
evidence suggests that the rat may not adequately reﬂect human
pharmacology, the use of NHP may be more appropriate. But,
where no strong scientiﬁc rationale for the use of a particular
species exists, more pragmatic issues will invariably guide deci-
sions regarding species choice for self-administration studies and
it may be more appropriate to use the rat (for a discussion of these
issues, see Section 6).
4.2. Genetic factors (strain and sex)
A variety of rat strains have been used for self-administration
studies and this variable can inﬂuence the outcome of studies.
For example, etonitazine was self-administered in both Wistar and
Lewis rats, but not Fisher 344 rats (Carroll and Boe, 1982; Suzuki
et al., 1992). The inﬂuence of rat strain on self-administration study
outcomes has also been demonstrated for the cannabinoid recep-
tor agonist WIN 55,212-2 (Deiana et al., 2007), ethanol (Wilson
et al., 1997), cocaine (Ward et al., 1996) and amphetamine (Meyer
et al., 2010). These ﬁndings could reﬂect, in part, strain differences
in drug metabolism (Sziraki et al., 2001) or neurobiology (Dalley
et al., 2007), or may simply reﬂect an optimisation of methodology
appropriate for some strains but not others.In addition to strain, animal sex is also likely to inﬂuence study
ﬁndings. For example, phencyclidine supported the acquisition of
self-administration more readily in female than male rhesus mon-
keys (Carroll et al., 2000). Similarly, female rats self-administered
more morphine (Alexander et al., 1978), fentanyl (Alexander et al.,
E.C. O’Connor et al. / Neuroscience and Biobehavioral Reviews 35 (2011) 912–938 929
Table 5
Summary of discrepancies between ﬁndings from non-clinical self-administration studies and two clinical indicators of abuse liability. Discrepancies between self-
administration studies in rats (R) and non-human primates (NHP) and one or both clinical indicators of abuse liability were classiﬁed as representing either false positives
(that is, reports of self-administration in animals but absence of reports of positive subjective-effects and/or scheduling status) or false negatives (that is, absence of self-
administration in animals, but reports of positive subjective-effects and/or scheduling status). 1: no evidence of consideration for drug scheduling available; 2: no published
NHP data; 3: no published clinical reports of positive subjective-effects.
Discrepancy between non-clinical self-administration and: Positive subjective-effects Drug scheduling status
False positive False negative False positive False negative
1. Both clinical endpoints
Bromocriptine R, NHP R, NHP
Clonidine R, NHP R, NHP
Haloperidol R R
Imipramine R R
Modaﬁnil R R
Nomifensine R, NHP R, NHP
Phenylpropanolamine R R
2. Positive subjective-effects only
Cyclazocine R, NHP
Dextrometorphan R
Flurazepam R, NHP
Ketocyclazocine1 NHP
Levallorphan R, NHP
Testosterone2 R
Tripelennamine R
3. Drug scheduling status only
Apomorphine3 R, NHP
Bupropion R, NHP
Caffeine R, NHP
Dextrometorphan NHP
Diphenhydramine R, NHP
Ephedrine R, NHP
Ethanol R, NHP
Fenﬂuramine R, NHP
Hexobarbital3 R
Nalbuphine R, NHP
Nicotine R, NHP
Propofol R, NHP
Scopolamine3 R, NHP
1
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Tripelennamine
Varenicline2
978) and alcohol (Lancaster and Spiegel, 1992) thanmale rats. The
ontribution of sex differences to the behavioural effects of abused
ubstanceshavebeenwell discussedelsewhere in studiesusing rats
Hu et al., 2004; Lynch, 2006; Lynch et al., 2000; Lynch and Carroll,
999; Lynch and Taylor, 2004; Roth et al., 2004), NHPs (Grant and
ennett, 2003; Newman et al., 2006; Pakarinen et al., 1999) and
umans (Fattore et al., 2008).
Relative differences in drug intake are typically observed as
function of strain and/or sex, rather than an absolute change
n the ability of a drug to function as a reinforcer in one strain
nd/or sex but not another. Nevertheless, meta-analyses that more
losely examine the inﬂuence of rat strain and/or sex on drug
elf-administration behaviour are warranted to enable a more
n-depth understanding of the inﬂuence of these factors. This
ay be of greater relevance where compounds are being devel-
ped for gender-speciﬁc indications. To some extent, the inﬂuence
f genetic factors can be minimized by ensuring the inclusion
f an appropriate positive control (see Section 5.3). Thus, self-
dministration of the positive control in a particular strain and/or
ex can increase conﬁdence in the interpretation of negative ﬁnd-
ngs for a test drug when assessed under identical conditions to
hose used for the positive control..3. Food deprivation state
Food restriction is commonly employed in self-administration
tudies, and typically leads to an increase in the sensitivity of the rat
elf-administration model for detecting drug reinforcement. Thus,R, NHP
NHP
R
chronic food restriction can facilitate the acquisition of drug self-
administration, lower the threshold reinforcing dose, increase total
drug consumption and increase the effort subjects are willing to
exert in order to obtain drug (Campbell and Carroll, 2001; Carroll
et al., 1979).
However, food deprivation state may markedly inﬂuence the
predictive validity of the model. For example, phentermine sup-
ported self-administration in food deprived rats but not in rats
given free access to food (Papasava et al., 1985). An inﬂuence of
food deprivation state on rat self-administration study outcomes
has been reported for a variety of drugs including THC (Takahashi
and Singer, 1980), etonitazine (Carroll and Meisch, 1981), cocaine
(Oei, 1983), phencyclidine (Carroll et al., 1981) andd-amphetamine
(Glick et al., 1987), but not fenﬂuramine (Papasava et al., 1986).
Similar inﬂuences of food restriction have been reported in NHP
self-administration studies (for example, Comer et al., 1995) and
interestingly, strong relationships between eating behaviours and
drug abuse have been reported in humans (see Carr, 2007 for
review).
While food deprivation may prove beneﬁcial for detecting drug
reinforcement, it is not unreasonable to propose that manip-
ulation of this variable could increase the occurrence of false
negative or false-positive ﬁndings. Further empirical studies and/or
meta-analyses that more closely examine the inﬂuence of food
deprivation state on drug self-administration behaviour would be
of great value to understand the inﬂuence of this factor on self-
administration study outcomes. Food deprivation state should be
given careful consideration, although again the inclusion of an
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ppropriate positive control (see Section 5.3) can add conﬁdence to
ndings for a test drug when assessed under identical conditions
s the positive control.
.4. Study design and drug history
Non-clinical self-administration study designs can be broadly
ategorised into two paradigms. In ‘acquisition studies’ the ability
f the test drug to support the learning of a novel operant response
s examined using drug-naïve animals. In ‘substitution studies’ the
bility of the test drug to reinforce operant responding is examined
n animals with prior drug self-administration experience.
Drug substitution paradigms for self-administration studies
ave some clear advantages in terms of the number of animals
sed and cost (Ator and Grifﬁths, 2003). But, perhaps the most
igniﬁcant advantage of substitution paradigms is that they pos-
ess greater face validity in terms of modelling the potential for
rug abuse in recreational drug abusers. Substitution paradigms
an also be considered more analogous to human abuse liability
ests that use volunteers with histories of drug use (Carter and
rifﬁths, 2009). However, there remain important considerations
egarding the design and interpretation of substitution studies in
nimals, whichmay inﬂuence predictive validity. Notably, the drug
xperience of the animal prior to receiving the test drug (that
s, the drug history) can markedly inﬂuence subsequent respond-
ng for the test drug. For example, Hoffmeister and Schlichting
1972) reported that rhesus monkeys trained to self-administer
odeine subsequently self-administered higher levels of narcotic
nd non-narcotic analgesics and showed less intra-individual vari-
bility than monkeys trained to self-administer cocaine. Similarly,
n single substitution sessions in rhesus monkeys, responding was
ot observed for phencyclidine, dexoxadrol and dextrorphanwhen
ubstituted for codeine, but was observed when these drugs were
ubstituted for ketamine (Young and Woods, 1981).
Although drug substitution designs may prove more sensi-
ive for detecting drug reinforcement, the beneﬁts of acquisition
esigns should not be overlooked. Acquisition studies allow the
trictest assessment of a compounds reinforcing efﬁcacy, in that
positive signal can only reﬂect drug-induced reinforcement and
s immune from the inﬂuence of any previously acquired associ-
tions. However, negative ﬁndings from acquisition studies can
rove difﬁcult to interpret, since they may arise when any num-
er of experimental variables are not appropriate or optimal for
hat particular drug (see Section 5.3 for further discussion).
Our review identiﬁed examples where discrepancies between
ndings could potentially be attributed to the study design and/or
he drug history of the animals. In particular, a number of dis-
repancies were identiﬁed amongst different self-administration
tudies for the same GABAergic drug in both rats and NHPs (for
xample, chlordiazepoxide, diazepam and ﬂurazepam). Although
hese discrepancies could reﬂect relativelyweak reinforcing effects
f these drugs or subtle methodological differences, they may
lso highlight the importance of the study design. For example,
hlordiazepoxide supported the acquisition of self-administration
n drug-naive rats (Davis et al., 1987) and maintained self-
dministration in rats previously trained to self-administer
thanol, but not in previously cocaine trained rats (Falk and
ang, 1989a). Similarly, ﬂurazepam supported self-administration
n NHPs trained to self-administer a CNS depressant, but self-
dministration of ﬂurazepam was considered equivocal in NHPs
rained to self-administer a CNS stimulant (see Table 3 for refer-
nces). Further empirical studies are required to fully understand
nd optimise the study design and/or drug history conditions
equired to accurately assess the abuse potential of GABAergic
rugs in the rat self-administration model.havioral Reviews 35 (2011) 912–938
The inﬂuence of study design on the outcome of non-clinical
self-administration studies is mirrored by clinical studies where
the prior drug experience of human volunteers can markedly inﬂu-
ence reports of subjective-effects. For example, both diazepam and
GHB induced positive outcomes in clinical subjects who were reg-
ular users of CNS depressants, but not in drug-naïve or recreational
drug users (Carter et al., 2006; Ferrara et al., 1999; Singh et al.,
2001). Similarly, nicotine produced reports of positive subjective-
effects in smokers, but not non-smokers (Soria et al., 1996) and
methylphenidate produced subjective reports of ‘liking’ in psy-
chomotor stimulant users but not non-dependent light drug users
at comparable doses (Heil et al., 2002; Heishman and Henningﬁeld,
1991).
In rats, dextromethorphan and modaﬁnil did not support self-
administration when assessed under acquisition conditions, but
both drugs are associated with abuse liability (see Table 4 for
references). Similarly, the antihistamines diphenhydramine and
tripelennamineeither failed to support self-administration indrug-
naïve rats (Fuchs and Coper, 1986) or were self-administered
by only a few of the experimental animals (Jun et al., 2004).
Although diphenhydramine and tripelennamine are not controlled
substances, both drugs produced reports of positive subjective-
effects (see Table 2 for references) and the abuse of CNS active
antihistamineshasbeen recognised (Thomaset al., 2009). Critically,
while these fourdrugs failed to support self-administration indrug-
naïve rats, all four drugs reliably supported self-administration in
NHPs with prior drug experience. Thus, for the purpose of advanc-
ing our understanding of the predictive validity of the rat for abuse
liability, itwill be of great value to understandwhether any of these
drugs could support self-administration in drug experienced rats.
5. Improving the predictive validity of the
self-administration model
5.1. Understanding relative reinforcing efﬁcacy
The present review collated information on whether or not a
drug supported self-administration in animals and whether or not
a drug was associated with abuse liability in humans. In truth, this
‘binary approach’ represents a superﬁcial viewof abuse liability and
a key area for future focus will be to understand not only if a com-
pound is likely to possess abuse liability, but what the relative risk
of abuse liability will be. Understanding the relative risk of abuse
liability will require advancement of both non-clinical models of
abuse potential and the clinical indicators used to assess abuse risk
(for further discussion see Conway et al., 2010; Katz, 1990; Nutt
et al., 2007).
In the animal drug self-administration model, advancements in
understanding the reinforcing effects of a drug relative to other
comparator agents (termed, relative reinforcing efﬁcacy) include
the incorporation of more complex reinforcement schedules, such
as the progressive ratio (PR) schedule (Gardner, 2000; Katz, 1990;
Richardson and Roberts, 1996; Rowlett, 2000; Stafford et al., 1998),
choice procedures (Negus, 2003;Ward et al., 2005) and the applica-
tion of behavioural economics to generate demand curves based on
a labour-supply analysis (Hursh, 1980; Rowlett, 2000). Two addi-
tional models developed within the sphere of addiction research
may also hold promise for predicting relative risk of abuse liability.
In the binge self-administration model, rats given extended access
to cocaine are observed to escalate drug intake relative to rats pro-
vided with only short periods of drug access (Ahmed and Koob,
1998).Using thismodel, itmaybeof interest tounderstandwhether
drugs that demonstrate greater propensity for abuse are also more
likely to support the escalation of drug intake. Secondly, continued
drug self-administration in the face of punishment (such as a mild
Biobe
e
(
f
r
d
p
a
t
t
t
t
b
m
a
j
r
o
F
a
w
r
ﬁ
t
m
e
i
e
r
r
h
h
e
a
c
d
i
t
h
l
5
t
t
p
m
i
p
p
m
S
e
r
o
m
d
i
p
t
s
tE.C. O’Connor et al. / Neuroscience and
lectric shock) is considered to model one aspect of drug addiction
Deroche-Gamonet et al., 2004), but this model may also be use-
ul to determine relative reinforcing efﬁcacy. Thus, relatively weak
einforcers may fail to support drug self-administration under con-
itions of punishment (but see Davis, 1968 for an example where
unishment may increase self-administration behavior). Consider-
ble research is still required to fully understand whether these
wo models have utility in abuse liability research. Traditionally,
he assessment of abuse potential, as opposed to addiction poten-
ial has been considered sufﬁcient as a preclinical contribution to
he scheduling recommendation, basedonanassumed relationship
etween abuse potential and addictive potential. While the use of
odels more closely aligned to addiction potential may be valu-
ble in differentiating between drugs, their use should be clearly
ustiﬁed and based on testing clear hypotheses.
For some of the false-positive ﬁndings identiﬁed in the present
eview, an assessment of relative reinforcing efﬁcacy in animals
ffered a more accurate reﬂection of abuse liability risk in humans.
or example, tramadol maintained self-administration in both rats
nd NHPs, but was identiﬁed as a weak reinforcer relative to drugs
ith known abuse liability when examined under a PR schedule of
einforcement (O’Connor and Mead, 2010; Yanagita, 1978). These
ndings are entirely consistent with clinical studies indicating that
ramadol doespossess abuse liability, although the incidenceof tra-
adol abuse is far lower than for typical opioid analgesics (Epstein
t al., 2006). Similarly, varenicline maintained self-administration
n rats, but is not associated with abuse liability in humans (McColl
t al., 2008). However, when assessed using a PR schedule in the
at self-administration model, varenicline was identiﬁed as a weak
einforcer relative to nicotine (Rollema et al., 2007).
It is likely that more accurate predictions of abuse liability may
ave been made for other false positives identiﬁed in our review,
ad assessments of relative reinforcing efﬁcacy been employed. For
xample, the adrenergic drugs clonidine and ephedrine were self-
dministered in rats and NHPs (see Table 2 for references) while
linically, these drugs are identiﬁed as weak reinforcers relative to
rugs with high risk of abuse liability (Chait, 1994). Further stud-
es of relative reinforcing efﬁcacy will be critical for understanding
hemethodological variables that inﬂuence these assessments, and
ow ﬁndings from these approaches translate to relative abuse
iability risk in humans.
.2. Pharmacokinetic modelling and adverse event proﬁles
A unique feature of the self-administration model is that the
otal drug dose administered is dependent on the behaviour of
he animal. This is in stark contrast to the majority of behavioural
harmacology and safety studies, where the effects of an experi-
enter deﬁned dose are assessed. By assessing the pattern of drug
nfusions from self-administration studies and applying in-silico
harmacokinetic (PK) modelling methods to these data, it may be
ossible to understand drug exposure levels that are optimal for
aintaining reinforcement in animals (Crespo et al., 2006; Lau and
un, 2002; Tsibulsky and Norman, 2005).
Although still in its infancy, the potential strength of PK mod-
lling for self-administration studies lies in understanding the
elationshipbetweendrugexposure levels (ordrug targetonset and
ffset rates) necessary for maintaining drug reinforcement in ani-
als relative to clinical efﬁcaciousdose levels and, critically, clinical
ose levels associated with side effects that may limit abuse liabil-
ty (for example, nausea or seizures). With this information, abuse
otential researchers may be able to better predict and minimize
he likelihood of abuse.
Based on the studies included in the present review,we can only
peculate about the advantages that PK modelling together with
he integration of adverse event proﬁles could offer for predictinghavioral Reviews 35 (2011) 912–938 931
risk of abuse liability. However, we propose that the abuse liability
of a number of drugs may have been better predicted by taking
this approach. First, bupropion supported self-administration in
rats and NHPs, but is not associated with abuse liability in humans.
Although the reason for this discrepancy is not fully understood
(but see Tella et al., 1997), onepossible explanation is that the intra-
venous route of administration in non-clinical studies facilitated a
rate of drug onset and drug exposure levels necessary to support
drug reinforcement in animals, while clinically bupropion is mar-
keted as a slow release oral formulation that is likely to preclude
such effects in humans (Dwoskin et al., 2006; Stathis et al., 1995).
Further, attempts to misuse bupropion via nasal insufﬂation have
been reported to result in seizures, which may further limit the
abuse of this drug (Kim and Steinhart, 2010). Second, both apomor-
phine and bromocriptine were self-administered in rats and NHPs,
but neither drug is associated with abuse liability. Critically, both
drugs are associated with adverse reactions in humans that may
limit their potential for abuse (LeWitt et al., 2009; Preston et al.,
1992a). Third, varenicline was self-administered in rats but is not
associated with abuse liability in humans. Findings from a clinical
abuse potential study demonstrated that although varenicline pro-
duced a ‘drug high’ in non-smokers at drug levels that exceeded
efﬁcacious doses, these reports also corresponded with reports
of nausea. Thus, reports of a ‘drug high’ following varenicline
administration were unlikely to be positive in nature and these
ﬁndings likely underwrite the lack of varenicline abuse (McColl
et al., 2008). Finally, although tramadol was self-administered in
rats and NHPs, an appreciation of tramadol’s complex pharmaco-
logical and metabolic proﬁle provides a substantial account for it’s
limited abuse liability (see O’Connor and Mead, 2010 for further
discussion).
5.3. Selecting appropriate control substances
Without appropriate control substances, negative ﬁndings from
drug self-administration studies aredifﬁcult to interpret, since they
may occur when any number of experimental variables (including
response-contingencies, infusion rates, drug-paired environmen-
tal stimuli, dose, schedule of reinforcement, daily schedule of drug
access and route of drug administration) are not appropriate or
optimal for the particular test drug. To overcome these concerns,
the selectionof appropriate positive andnegative controls is critical
for all self-administration studies.
A positive control should clearly support robust drug self-
administration in animals and as such is often used as the training
drug in substitution based paradigms. But, there are a number
of other considerations that should be taken into account when
selecting an appropriate control substance andwhichmay improve
the predictive validity of the model. Ideally, the positive control
should be selected from the same pharmacological class as the test
drug, since the conditions required for robust self-administration
behaviour can differ across drug classes. Where an appropriate
positive control cannot be identiﬁed based on pharmacology (for
example, where the test drug has a novel or unknown mechanism
of action), a positive control that produces a similar behavioural
proﬁle as the test drug may serve as the most appropriate com-
parator agent. Where neither pharmacology nor the behavioural
proﬁle of the test drug can be used to select an appropriate positive
control, scheduled drugs that share the intended clinical indication
as the test substance may provide useful comparator agents.
Other criteria for selecting positive control agents may take
into account the metabolic proﬁle of the test agent. For example,
remifentanil, rather than morphine, may offer a more appropriate
positive control for anovel opioid relateddrugwitha shortduration
of action. Control substances may also be chosen to help differenti-
ate between the test druganddrugs indifferent scheduling levels or
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oprovide a direct comparator to control substances used in clinical
busepotential studies. Finally, unscheduleddrugsordrugs that are
ot abused, but yet give positive signals (for example, bupropion)
ay be included to provide context, since such drugs can highlight
he limitations, sensitivity or principles of the self-administration
odel.
Equally important as the inclusion of an appropriate positive
ontrol is the inclusion of a negative control (that is, a substance
evoid of abuse liability) which can be used to deﬁne a negative
ignal under the particular test conditions. Typically, the vehicle
f the test substance provides the most appropriate and conve-
ient negative control. A drug that is devoid of abuse liability, but
hich shares a similar mechanism of action and/or is marketed for
he same clinical indication as the test drug may also serve as an
nformative negative control substance.
. Discussion
This report provides an overview of ﬁndings from self-
dministration studies conducted in rats with a view to
nderstanding the predictive validity of the rat self-administration
odel for assessing the risk of abuse liability. Our ﬁndings show
hat outcomes from rat self-administration studies, which encom-
ass a broad range of drug classes, show high concordance with
wo clinical indicators of abuse liability, namely reports of posi-
ive subjective-effects (that is, ‘liking’, ‘euphoria’ and/or ‘high’) and
rug scheduling status. These ﬁndings lend support to previous
omments that the self-administration model represents a critical
omponent of drug abuse liability assessments (Ator and Grifﬁths,
003; Balster, 1991; Carter and Grifﬁths, 2009).
Understanding the predictive strengths and limitations of the
elf-administration model depends heavily upon the number of
ublished studies available for each drug and, in turn, the num-
er of drugs that have been assessed within a particular drug class.
hile it is not possible to state the minimum number of studies
equired to fully understand the predictive validity of the model
or any given drug or drug class (one well designed study may be
ore convincing than three poorly conceived studies), conﬁdence
n the model will invariably increase in line with the number of
ublished studies that use a variety of methodologies. Our review
dentiﬁed a number of speciﬁc drug cases where further studies
ould be beneﬁcial to fully understand the predictive validity of
he rat self-administration model (for example, haloperidol, hexo-
arbital, and modaﬁnil). Similarly, studies of additional drugs are
equired to fully understand the strengths and limitations of the rat
odel for use in assessing the abuse liability of certain drug classes
in particular, cannabinoids, steroids and adenosinergic drugs).
Assessing the predictive validity of non-clinical models also
epends heavily on the strength of the chosen clinical endpoint to
hich the model is compared (see Katz (1990) for further discus-
ion of this issue). Thus, one of the major challenges for this review
as to select reliable indicators of abuse liability. As highlighted in
he following discussion, a number of limitations associated with
he use of subjective-effects studies and drug scheduling status
or indicating abuse liability are acknowledged and, in some cases,
hese limitations may have contributed to discrepancies identiﬁed
etween non-clinical studies and the clinical or regulatory indica-
ors of abuse liability.
With respect to reports of subjective-effects, restricting this
easure to reports of positive effects (that is, ‘liking’, ‘euphoria’nd/or ‘high’) precluded incorporation of other subjective-effects,
uch as dysphoria or nausea, which may limit the overall abuse
iability of a compound. For example, although levallorphan engen-
ered reportsofpositive subject effects, it producedoverall changes
n subjective-effects that were quite distinct from those of mor-havioral Reviews 35 (2011) 912–938
phine and other narcotic analgesics (Jasinski et al., 1967). Second,
it is recognised that different scales of positive subjective-effects
maynotdirectly correlate andcanhavediffering sensitivities across
different drug classes. For example, non-drug abusing volunteers
reported signiﬁcant ‘drug liking’, but not a ‘drug high’ following
administration of morphine (Zacny and Gutierrez, 2003). Third, it
has been argued that drug reinforcement and subjective responses
in humans are dissociable phenomena (Henningﬁeld et al., 1987;
Johanson and Uhlenhuth, 1981; Lamb et al., 1991; Martinez et al.,
2004), thus reports of positive subjective-effects may have limited
use in providing a direct clinical comparison to non-clinical studies
that examine drug reinforcement.
Drug scheduling statuswas chosen as a second clinical indicator
of abuse liability, since it could potentially offer a more compre-
hensive reﬂection of ‘real-world’ abuse liability than reports of
positive subjective-effects alone. However, a number of drugs with
recognised abuse liability are not currently listed as controlled sub-
stances (most notably, nicotine and ethanol but also see propofol,
dextromethorphan and diphenhydramine). Consequently, ﬁndings
from some non-clinical studies that were identiﬁed as discrepant
with respect to the drug scheduling status could readily be
attributed to inconsistencies between the scheduling status and
published clinical reports of drug abuse.
To overcome the limitations associated with reports of
subjective-effects and drug scheduling status, one must look to
other clinical endpoints of abuse liability. Recent reviewers have
noted that ﬁndings from human self-administration studies are
more predictive of abuse liability than reports of subjective-effects
alone (Fischman and Foltin, 1991; Haney and Spealman, 2008).
In conducting our review, we found that studies of drug self-
administration in humans were limited to only a few of the drugs
that were included in this review. If this model is used more rou-
tinely and consistently in the clinic, it may serve as a valuable
clinical indicator of abuse liability against which the predictive
validity of non-clinical self-administration studies can be com-
pared.
Our current review identiﬁed relatively few cases where
discrepancies between rat self-administration studies and the
clinical endpoints of abuse liability were not mirrored by self-
administration studies conducted using NHPs. Thus, where no
strong scientiﬁc rational for the use of a particular species exist,
more pragmatic issues will invariably guide decisions regarding
species choice for self-administration studies. Rats and NHPs each
have their own beneﬁtswhichmust be considered against the aims
of the study. A clear beneﬁt for using NHPs is that catheter patency
can be maintained for a longer period of time than is typical in the
rat, permitting theuse ofmore complex schedules of reinforcement
and allowing for complete within-subject designs. In addition,
NHPs often have self-administration experience that encompasses
a variety of drug classes, which may offer greater validity for mod-
elling the potential for drug misuse in human poly-drug abusers.
However, rats offer a number of distinct advantages over NHPs in
terms of cost, care, and availability. Rat self-administration studies
can therefore be used early in drug development to enable critical
decisions on whether to continue investigating a novel compound
or target. Further,muchofnon-clinical drugdiscovery anddevelop-
ment is performed in the rat, thus facilitating the design of abuse
potential studies with the added knowledge of efﬁcacious doses,
pharmacodynamic andmetabolic proﬁles and adverse drug effects.
Finally, there are ethical considerations regarding the selection of
species for animal experimentation. The selection of species for
use in animal research with the lowest degree of neurophysiologic
sensitivity, termed ‘phylogenetic reduction’, is in line with Euro-
pean regulations (European Union (2010) Directive 2010/63/EU)
and UK national legislation, which gives special protection to the
use of cats, dogs and primates in animal research (UK Government,
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nimals (Scientiﬁc Procedures) Act, 1986). Phylogenetic reduction
s also consistent with recent regulatory guidance on the non-
linical investigation of dependence potential, stating that rodents
r other non-primate models deserve preference above primate
odels where available, provided the chosen species is appropri-
te for the active substance tested and the model is validated and
echnically feasible (EMEA, 2006; ICHM3 (R2), 2010).
In summary, the current review conﬁrms the rat self-
dministration model as a valuable tool for use in assessments of
buse liability. Given the number of experimental variables that
an inﬂuence study outcomes, the design of rat self-administration
tudieswill be critical for determining thepredictive strengthof the
odel when used in assessments of abuse liability for novel CNS
ctive drugs. A number of exciting opportunities exist to enhance
he predictive validity of the self-administration model, including
he development of robust methods to assess relative reinforcing
fﬁcacy and using PK modelling methods to understand the rela-
ionship between drug dose levels necessary for supporting drug
einforcement relative to dose levels associated with adverse clin-
cal events, which may serve to limit abuse liability. However, one
ust remember that the drug self-administration model measures
nly one of many factors that can contribute to abuse liability (that
s, drug reinforcement). Thus ‘real world’ assessments of abuse lia-
ility that integrate data from a variety of non-clinical and clinical
buse potential models will invariably provide a more accurate
ssessment of abuse liability risk than data from any one abuse
otential model (Ator and Grifﬁths, 2003; Carter and Grifﬁths,
009; Haney and Spealman, 2008; Mansbach et al., 2003; O’Connor
ndMead, 2010). Anongoing challenge for abusepotential research
ill be to continue developing and reﬁning non-clinical and clinical
odels of abuse potential, and determine how best to incorporate
ata from multiple sources in order to maximize the predictive
trength of abuse liability assessments and thereby minimize risk
o public health.
onﬂict of interest/Role of funding source
At the time the manuscript was initiated, Eoin O’Connor was
Pﬁzer employee. Eoin O’Connor currently receives a DPhil stu-
entship from the BBSRC and Pﬁzer. Andy Mead and Paul Butler
re employees of Pﬁzer. Kathryn Chapman is an employee of the
C3Rs. This review was sponsored by Pﬁzer and the NC3Rs. The
uthors took sole responsibility for the initiation and design of the
eview, the collection and interpretation of data, the writing of the
eport and the decision to submit the paper for publication.
eferences
hmed, S.H., Koob, G.F., 1998. Transition from moderate to excessive drug intake:
change in hedonic set point. Science 282, 298–300.
igner, T.G., Balster, R.L., 1979. Rapid substitution procedure for intravenous drug
self-administration studies in rhesus monkeys. Pharmacol. Biochem. Behav. 10,
105–112.
lderson, H.L., Robbins, T.W., Everitt, B.J., 2000. Heroin self-administration under
a second-order schedule of reinforcement: acquisition and maintenance of
heroin-seeking behaviour in rats. Psychopharmacology (Berl) 153, 120–133.
lexander, B.K., Coambs, R.B., Hadaway, P.F., 1978. The effect of housing and gen-
der on morphine self-administration in rats. Psychopharmacology (Berl) 58,
175–179.
nderson, K.G., Winger, G., Woods, J., Woolverton, W.L., 2001. Reinforcing and
discriminative-stimulus effects of ephedrine isomers in rhesus monkeys. Drug
Alcohol Depend. 65, 45–53.
tkinson, J., Enslen, M., 1976. Self-administration of caffeine by the rat. Arzneimit-
telforschung 26, 2059–2061.
tor, N.A., 2002. Relation between discriminative and reinforcing effects of mida-
zolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons.
Psychopharmacology (Berl) 163, 477–487.
tor, N.A., Grifﬁths, R.R., 1983. Nicotine self-administration in baboons. Pharmacol.
Biochem. Behav. 19, 993–1003.
tor, N.A., Grifﬁths, R.R., 2003. Principles of drug abuse liability assessment in labo-
ratory animals. Drug Alcohol Depend. 70, S55–S72.havioral Reviews 35 (2011) 912–938 933
Balster, R.L., 1991. Drug abuse potential evaluation in animals. Br. J. Addict. 86,
1549–1558.
Balster, R.L., Bigelow, G.E., 2003. Guidelines and methodological reviews concerning
drug abuse liability assessment. Drug Alcohol Depend. 70, S13–S40.
Balster, R.L., Schuster, C.R., 1973. A comparison of d-amphetamine, l-amphetamine,
and methamphetamine self-administration in rhesus monkeys. Pharmacol.
Biochem. Behav. 1, 67–71.
Baylon, G.J., Kaplan, H.L., Somer, G., Busto, U.E., Sellers, E.M., 2000. Comparative
abuse liability of intravenously administered remifentanil and fentanyl. J. Clin.
Psychopharmacol. 20, 597–606.
Beardsley, P.M., Aceto,M.D., Cook, C.D., Bowman, E.R.,Newman, J.L.,Harris, L.S., 2004.
Discriminative stimulus, reinforcing, physical dependence, and antinociceptive
effects of oxycodone in mice, rats, and rhesus monkeys. Exp. Clin. Psychophar-
macol. 12, 163–172.
Beardsley, P.M., Balster, R.L., 1992. The intravenous self-administration of antihis-
tamines by rhesus monkeys. Drug Alcohol Depend. 30, 117–126.
Beardsley, P.M., Balster, R.L., Harris, L.S., 1996. Evaluation of the discriminative
stimulus and reinforcing effects of gammahydroxybutyrate (GHB). Psychophar-
macology (Berl) 127, 315–322.
Beardsley, P.M., Harris, L.S., 1997. Evaluation of the discriminative stimulus and
reinforcing effects of dihydroetorphine. Drug Alcohol Depend. 48, 77–84.
Bergman, J., Johanson, C.E., 1985. The reinforcing properties of diazepam under sev-
eral conditions in the rhesus monkey. Psychopharmacology (Berl) 86, 108–113.
Bergman, J., Madras, B.K., Johnson, S.E., Spealman, R.D., 1989. Effects of cocaine
and related drugs in nonhuman primates. III. Self-administration by squirrel
monkeys. J. Pharmacol. Exp. Ther. 251, 150–155.
Bergman, J., Spealman, R.D., 1986. Some behavioral effects of histamine H1 antago-
nists in squirrel monkeys. J. Pharmacol. Exp. Ther. 239, 104–110.
Bowdle, T.A., Radant, A.D., Cowley, D.S., Kharasch, E.D., Strassman, R.J., Roy-Byrne,
P.P., 1998. Psychedelic effects of ketamine in healthy volunteers: relationship to
steady-state plasma concentrations. Anesthesiology 88, 82–88.
Brady, J.V., Grifﬁths, R.R., 1976. Behavioral procedures for evaluating the relative
abuse potential of CNS drugs in primates. Fed. Proc. 35, 2245–2253.
Brauer, L.H., Johanson, C.E., Schuster, C.R., Rothman, R.B., deWit, H., 1996. Evaluation
of phentermine and fenﬂuramine, alone and in combination, in normal, healthy
volunteers. Neuropsychopharmacology 14, 233–241.
Brenneisen,R., Fisch,H.U.,Koelbing,U.,Geisshusler, S., Kalix, P., 1990.Amphetamine-
like effects in humans of the khat alkaloid cathinone. Br. J. Clin. Pharmacol. 30,
825–828.
Briscoe, R.J., Vanecek, S.A., Vallett, M., Baird, T.J., Holloway, F.A., Gauvin, D.V., 1998.
Reinforcing effects of caffeine, ephedrine, and their binary combination in rats.
Pharmacol. Biochem. Behav. 60, 685–693.
Broadbear, J.H., Winger, G., Woods, J.H., 2004. Self-administration of fentanyl,
cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys.
Psychopharmacology (Berl) 176, 398–406.
Broadbear, J.H., Winger, G., Woods, J.H., 2005. Self-administration of methohexital,
midazolamandethanol: effects on thepituitary-adrenal axis in rhesusmonkeys.
Psychopharmacology (Berl) 178, 83–91.
Caine, S.B., Lintz, R., Koob, G.F., 1993. Intravenous Drug Self-administration Tech-
niques in Animals. Oxford University Press, Oxford.
Cami, J., Farre, M., Mas, M., Roset, P.N., Poudevida, S., Mas, A., San, L., de la Torre,
R., 2000. Human pharmacology of 3,4-methylenedioxymethamphetamine
(“ecstasy”): psychomotor performance and subjective effects. J. Clin. Psy-
chopharmacol. 20, 455–466.
Cami, J., Lamas, X., Farre, M., 1994. Acute effects of tramadol in methadone-
maintained volunteers. Drugs 47 (Suppl. 1), 39–43.
Campbell, U.C., Carroll,M.E., 2001. Effects of ketoconazole on the acquisitionof intra-
venous cocaine self-administration under different feeding conditions in rats.
Psychopharmacology (Berl) 154, 311–318.
Carr, K.D., 2007. Chronic food restriction: enhancing effects on drug reward and
striatal cell signaling. Physiol. Behav. 91, 459–472.
Carroll, M.E., Boe, I.N., 1982. Increased intravenous drug self-administration during
deprivation of other reinforcers. Pharmacol. Biochem. Behav. 17, 563–567.
Carroll, M.E., France, C.P., Meisch, R.A., 1979. Food deprivation increases oral and
intravenous drug intake in rats. Science 205, 319–321.
Carroll, M.E., France, C.P., Meisch, R.A., 1981. Intravenous self-administration of
etonitazene, cocaine and phencyclidine in rats during food deprivation and
satiation. J. Pharmacol. Exp. Ther. 217, 241–247.
Carroll, M.E., Lac, S.T., 1997. Acquisition of i.v. amphetamine and cocaine self-
administration in rats as a function of dose. Psychopharmacology (Berl) 129,
206–214.
Carroll, M.E., Meisch, R.A., 1981. Determinants of increased drug self-administration
due to food deprivation. Psychopharmacology (Berl) 74, 197–200.
Carroll, M.E., Roth, M.E., Voeller, R.K., Nguyen, P.D., 2000. Acquisition of oral
phencyclidine self-administration in rhesusmonkeys: effect of sex. Psychophar-
macology (Berl) 149, 401–408.
Carroll, M.E., Stotz, D.C., 1983. Oral d-amphetamine and ketamine self-
administration by rhesus monkeys: effects of food deprivation. J. Pharmacol.
Exp. Ther. 227, 28–34.
Carter, L.P., Grifﬁths, R.R., 2009. Principles of laboratory assessment of drug abuse
liability and implications for clinical development. Drug Alcohol Depend. 105
(Suppl. 1), S14–S25.
Carter, L.P., Richards, B.D., Mintzer, M.Z., Grifﬁths, R.R., 2006. Relative abuse liabil-
ity of GHB in humans: a comparison of psychomotor, subjective, and cognitive
effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neu-
ropsychopharmacology 31, 2537–2551.
9 Biobe
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
D
D
D
d
d
D
D
D
D
D
D
D
D34 E.C. O’Connor et al. / Neuroscience and
hait, L.D., 1994. Factors inﬂuencing the reinforcing and subjective effects of
ephedrine in humans. Psychopharmacology (Berl) 113, 381–387.
hait, L.D., Uhlenhuth, E.H., Johanson, C.E., 1987. Reinforcing and subjective effects
of several anorectics in normal human volunteers. J. Pharmacol. Exp. Ther. 242,
777–783.
hilds, E., de Wit, H., 2006. Subjective, behavioral, and physiological effects of acute
caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 185,
514–523.
lark, R., Schuster, C.R., Brady, J.V., 1961. Instrumental conditioning of jugular self-
infusion in the rhesus monkey. Science 133, 1829–1830.
ole-Harding, S., de Wit, H., 1992. Self-administration of pentobarbital in light and
moderate alcohol drinkers. Pharmacol. Biochem. Behav. 43, 563–569.
ollins, R.J., Weeks, J.R., Cooper, M.M., Good, P.I., Russell, R.R., 1984. Prediction of
abuse liability of drugs using IV self-administration by rats. Psychopharmacol-
ogy (Berl) 82, 6–13.
olombo, G., Agabio, R., Balaklievskaia, N., Diaz, G., Lobina, C., Reali, R., Gessa, G.L.,
1995. Oral self-administration of gamma-hydroxybutyric acid in the rat. Eur. J.
Pharmacol. 285, 103–107.
olombo, G., Agabio, R., Diaz, G., Fa,M., Lobina, C., Reali, R., Gessa, G.L., 1998. Gamma-
hydroxybutyric acid intake in ethanol-preferring sP and -nonpreferring sNP rats.
Physiol. Behav. 64, 197–202.
omer, S.D., Collins, E.D., MacArthur, R.B., Fischman, M.W., 1999. Comparison of
intravenous and intranasal heroin self-administration bymorphine-maintained
humans. Psychopharmacology (Berl) 143, 327–338.
omer, S.D., Collins, E.D., Wilson, S.T., Donovan, M.R., Foltin, R.W., Fischman,
M.W., 1998. Effects of an alternative reinforcer on intravenous heroin self-
administration by humans. Eur. J. Pharmacol. 345, 13–26.
omer, S.D., Sullivan, M.A., Walker, E.A., 2005. Comparison of intravenous
buprenorphine and methadone self-administration by recently detoxiﬁed
heroin-dependent individuals. J. Pharmacol. Exp. Ther. 315, 1320–1330.
omer, S.D., Turner, D.M., Carroll, M.E., 1995. Effects of food deprivation on
cocaine base smoking in rhesusmonkeys. Psychopharmacology (Berl) 119, 127–
132.
one, E.J., Welch, P., Lange, W.R., 1988. Clonidine partially blocks the physiologic
effects but not the subjective effects produced by smoking marijuana in male
human subjects. Pharmacol. Biochem. Behav. 29, 649–652.
onway, K.P., Levy, J., Vanyukov, M., Chandler, R., Rutter, J., Swan, G.E., Neale, M.,
2010. Measuring addiction propensity and severity: the need for a new instru-
ment. Drug Alcohol Depend. 111 (1–2), 4–12.
orcoran, M.E., Amit, Z., 1974. Reluctance of rats to drink hashish suspensions: free-
choice and forced consumption, and the effects of hypothalamic stimulation.
Psychopharmacologia 35, 129–147.
orrigall, W.A., Coen, K.M., 1989. Nicotine maintains robust self-administration in
rats on a limited-access schedule. Psychopharmacology (Berl) 99, 473–478.
orwin, R.L., Woolverton, W.L., Schuster, C.R., Johanson, C.E., 1987. Anorectics:
effects on food intake and self-administration in rhesus monkeys. Alcohol Drug
Res. 7, 351–361.
respo, J.A., Panlilio, L.V., Schindler, C.W., Sturm, K., Saria, A., Zernig, G., 2006. Peri-
response pharmacokinetics of remifentanil during a self-administration session
indicates that neither blood nor brain levels are titrated. Ann. N. Y. Acad. Sci.
1074, 497–504.
alley, J.W., Fryer, T.D., Brichard, L., Robinson, E.S., Theobald, D.E., Laane, K., Pena,
Y., Murphy, E.R., Shah, Y., Probst, K., Abakumova, I., Aigbirhio, F.I., Richards,
H.K., Hong, Y., Baron, J.C., Everitt, B.J., Robbins, T.W., 2007. Nucleus accumbens
D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315,
1267–1270.
avis, J., 1968. Comparative studies of barbiturate self-administration. Int. J. Addict.
3, 207–214.
avis, W.M., Smith, T.E., Smith, S.G., 1987. Intravenous and intragastric self-
administration of chlordiazepoxide in the rat. Alcohol Drug Res. 7, 511–516.
e Wit, H., Uhlenhuth, E.H., Johanson, C.E., 1984. Lack of preference for ﬂurazepam
in normal volunteers. Pharmacol. Biochem. Behav. 21, 865–869.
e Wit, H., Pierri, J., Johanson, C.E., 1989. Reinforcing and subjective effects of
diazepam in nondrug-abusing volunteers. Pharmacol. Biochem. Behav. 33,
205–213.
eiana, S., Fattore, L., Sabrina Spano, M., Cossu, G., Porcu, E., Fadda, P., Fratta, W.,
2007. Strain and schedule-dependent differences in the acquisition, mainte-
nance and extinction of intravenous cannabinoid self-administration in rats.
Neuropharmacology 52, 646–654.
eneau, G., Yanagita, T., Seevers, M.H., 1969. Self-administration of psychoactive
substances by the monkey. Psychopharmacologia 16, 30–48.
eNoble, V.J., Mele, P.C., 2006. Intravenous nicotine self-administration in rats:
effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology
(Berl) 184, 266–272.
eNoble, V.J., Mele, P.C., Porter, J.H., 1985. Intravenous self-administration of pen-
tobarbital and ethanol in rats. Pharmacol. Biochem. Behav. 23, 759–763.
eroche-Gamonet, V., Belin, D., Piazza, P.V., 2004. Evidence for addiction-like behav-
ior in the rat. Science 305, 1014–1017.
eroche-Gamonet, V., Darnaudery, M., Bruins-Slot, L., Piat, F., Le Moal, M., Piazza,
P.V., 2002. Study of the addictive potential of modaﬁnil in naive and cocaine-
experienced rats. Psychopharmacology (Berl) 161, 387–395.
onny, E.C., Caggiula, A.R., Knopf, S., Brown, C., 1997. Nicotine self-administration
in rats. Psychopharmacology (Berl) 122, 390–394.
woskin, L.P., Rauhut, A.S., King-Pospisil, K.A., Bardo,M.T., 2006. Reviewof the phar-
macology and clinical proﬁle of bupropion, an antidepressant and tobacco use
cessation agent. CNS Drug Rev. 12, 178–207.havioral Reviews 35 (2011) 912–938
EMEA/CHMP/SWP/94227/2004. Guideline on the non-clinical investigation of the
dependence potential of medicinal products. London, 23 March 2006.
EuropeanUnion (2010) Directive 2010/63/EU of the European Parliament and of the
Council of 22 September 2010 on the protection of animals used for scientiﬁc
purposes. Ofﬁcial Journal of the European Union L 276/33.
Epstein, D.H., Preston, K.L., Jasinski, D.R., 2006. Abuse liability, behavioral pharma-
cology, and physical-dependence potential of opioids in humans and laboratory
animals: lessons from tramadol. Biol. Psychol. 73, 90–99.
Epstein, D.H., Silverman, K., Henningﬁeld, J.E., Preston, K.L., 1999. Low-dose oral
cocaine in humans: acquisition of discrimination and time-course of effects.
Behav. Pharmacol. 10, 531–542.
Ettenberg, A., Pettit, H.O., Bloom, F.E., Koob, G.F., 1982. Heroin and cocaine intra-
venous self-administration in rats: mediation by separate neural systems.
Psychopharmacology (Berl) 78, 204–209.
Falk, J.L., Tang, M., 1989a. Schedule-induced chlordiazepoxide intake: differential
effect of cocaine and ethanol histories. Pharmacol. Biochem. Behav. 33, 393–396.
Falk, J.L., Tang, M., 1989b. Schedule induction of drug intake: differential respon-
siveness to agents with abuse potential. J. Pharmacol. Exp. Ther. 249, 143–148.
Fantegrossi, W.E., Woods, J.H., Winger, G., 2004. Transient reinforcing effects of
phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys.
Behav. Pharmacol. 15, 149–157.
Fattore, L., Altea, S., Fratta, W., 2008. Sex differences in drug addiction: a review of
animal and human studies. Womens Health (Lond Engl) 4, 51–65.
Fattore, L., Cossu, G., Martellotta, C.M., Fratta, W., 2001. Intravenous self-
administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Psychopharmacology (Berl) 156, 410–416.
Fauman, B., Fauman, J.M.A., 1980. Chronic phenycyclidine (PCP) abuse: a psychiatric
perspective. Part II. Psychosis [proceedings]. Psychopharmacol. Bull. 16, 72–73.
FDA Guidance for industry. Assessment of Abuse Potential of Drugs. Draft Guidance
Jan 2010 U.S. Department of Health and Human Services, CDER.
Ferrara, S.D., Giorgetti, R., Zancaner, S., Orlando, R., Tagliabracci, A., Cavarzeran,
F., Palatini, P., 1999. Effects of single dose of gamma-hydroxybutyric acid and
lorazepam on psychomotor performance and subjective feelings in healthy vol-
unteers. Eur. J. Clin. Pharmacol. 54, 821–827.
Fingerhood,M.I., Sullivan, J.T., Testa,M., Jasinski, D.R., 1997. Abuse liability of testos-
terone. J. Psychopharmacol. 11, 59–63.
Finlay, J.M., Szostak, C., Fibiger, H.C., 1989. Further characterization of intravenous
self-administration of midazolam in the rat. Behav. Pharmacol. 1, 13–23.
Fischman, M.W., 1989. Relationship between self-reported drug effects and their
reinforcing effects: studies with stimulant drugs. NIDA Res. Monogr. 92,
211–230.
Fischman, M.W., Foltin, R.W., 1991. Utility of subjective-effects measurements in
assessing abuse liability of drugs in humans. Br. J. Addict. 86, 1563–1570.
Foltin, R.W., Fischman, M.W., 1991. Smoked and intravenous cocaine in humans:
acute tolerance, cardiovascular and subjective effects. J. Pharmacol. Exp. Ther.
257, 247–261.
Fraser, H.F., Van Horn, G.D., Martin, W.R., Wolbach, A.B., Isbell, H., 1961. Methods
for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-
like drugs. (B) a short-term “direct” addiction test. J. Pharmacol. Exp. Ther. 133,
371–387.
Frewer, L.J., Lader, M., 1993. The effects of nefazodone, imipramine and placebo,
aloneandcombinedwithalcohol, innormal subjects. Int. Clin. Psychopharmacol.
8, 13–20.
Fuchs, V., Coper, H., 1986. The inﬂuence of antihistamine compounds on the oral
intake of different addictive drugs. Drug Alcohol Depend. 17, 359–364.
Gardner, E.L., 2000. What we have learned about addiction from animal models of
drug self-administration. Am. J. Addict. 9, 285–313.
Garrett, B.E., Grifﬁths, R.R., 2001. Intravenous nicotine and caffeine: subjective and
physiological effects in cocaine abusers. J. Pharmacol. Exp. Ther. 296, 486–494.
Gerber, G.J., Bozarth, M.A., Spindler, J.E., Wise, R.A., 1985. Concurrent heroin self-
administration and intracranial self-stimulation in rats. Pharmacol. Biochem.
Behav. 23, 837–842.
Gerber, G.J., Stretch, R., 1975. Drug-induced reinstatement of extinguished self-
administrationbehavior inmonkeys. Pharmacol. Biochem.Behav. 3, 1055–1061.
Glick, S., 1982. Scopolamine self-administration: cholinergic involvement in reward
mechanisms. Life Sci. 31, 909–913.
Glick, S.D., Cox, R.S., 1975. Self-admimistration of haloperidol in rats. Life Sci. 16,
1041–1045.
Glick, S.D., Hinds, P.A., Carlson, J.N., 1987. Food deprivation and stimulant self-
administration in rats: differences between cocaine and d-amphetamine.
Psychopharmacology (Berl) 91, 372–374.
Gold, L.H., Balster, R.L., 1996. Evaluation of the cocaine-like discriminative stimu-
lus effects and reinforcing effects of modaﬁnil. Psychopharmacology (Berl) 126,
286–292.
Goldberg, S.R., Spealman, R.D., Goldberg, D.M., 1981. Persistent behavior at high
rates maintained by intravenous self-administration of nicotine. Science 214,
573–575.
Gomez, T.H., Roache, J.D., Meisch, R.A., 2002. Orally delivered alprazolam, diazepam,
and triazolamas reinforcers in rhesusmonkeys. Psychopharmacology (Berl) 161,
86–94.Gosnell, B.A., Yracheta, J.M., Bell, S.M., Lane, K.E., 1996. Intravenous self-
administration of cathinone by rats. Behav. Pharmacol. 7, 526–531.
Gotestam, K.G., 1973. Intragastric self-administration of medazepam in rats. Psy-
chopharmacologia 28, 87–94.
Gotestam, K.G., 1979. Investigations of abuse potential of anorectic drugs. Curr.Med.
Res. Opin. 6, 125–134.
Biobe
G
G
G
G
G
G
G
G
G
G
G
G
G
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
HE.C. O’Connor et al. / Neuroscience and
otestam, K.G., Andersson, B.E., 1975. Self-administration of amphetamine ana-
logues in rats. Pharmacol. Biochem. Behav. 3, 229–233.
rant, K.A., Bennett, A.J., 2003. Advances in nonhuman primate alcohol abuse and
alcoholism research. Pharmacol. Ther. 100, 235–255.
rant, K.A., Johanson, C.E., 1987. Diazepam self-administration and resistance to
extinction. Pharmacol. Biochem. Behav. 28, 81–86.
rant, K.A., Samson, H.H., 1985. Oral self administration of ethanol in free feeding
rats. Alcohol 2, 317–321.
rifﬁth, J.D., Carranza, J., Grifﬁth, C., Miller, L.L., 1983. Bupropion: clinical assay for
amphetamine-like abuse potential. J. Clin. Psychiatry 44, 206–208.
rifﬁths, R.R., Balster, R.L., 1979. Opioids: similarity between evaluations of sub-
jective effects and animal self-administration results. Clin. Pharmacol. Ther. 25,
611–617.
rifﬁths,R.R., Bigelow,G., Liebson, I., 1979.Humandrugself-administration:double-
blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J.
Pharmacol. Exp. Ther. 210, 301–310.
rifﬁths, R.R., Bigelow, G.E., Ator, N.A., 2003. Principles of initial experimental drug
abuse liability assessment in humans. Drug Alcohol Depend. 70, S41–S54.
rifﬁths, R.R., Bigelow, G.E., Liebson, I.A., 1989. Reinforcing effects of caffeine in
coffee and capsules. J. Exp. Anal. Behav. 52, 127–140.
rifﬁths, R.R., Lamb, R.J., Sannerud, C.A., Ator, N.A., Brady, J.V., 1991. Self-injection of
barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psy-
chopharmacology (Berl) 103, 154–161.
rifﬁths, R.R., Lukas, S.E., Bradford, L.D., Brady, J.V., Snell, J.D., 1981. Self-injection of
barbiturates and benzodiazepines in baboons. Psychopharmacology (Berl) 75,
101–109.
rifﬁths, R.R., Weerts, E.M., 1997. Benzodiazepine self-administration in humans
and laboratory animals – implications for problems of long-term use and abuse.
Psychopharmacology (Berl) 134, 1–37.
rifﬁths, R.R., Winger, G., Brady, J.V., Snell, J.D., 1976. Comparison of behavior
maintained by infusions of eight phenylethylamines in baboons. Psychophar-
macology (Berl) 50, 251–258.
aertzen, C.A., 1966. Development of scales based on patterns of drug effects,
using the addiction Research Center Inventory (ARCI). Psychol. Rep. 18, 163–
194.
aertzen,C.A., 1970. Subjectiveeffectsofnarcotic antagonists cyclazocineandnalor-
phine on the Addiction Research Center Inventory (ARCI). Psychopharmacologia
18, 366–377.
amilton, M.J., Smith, P.R., Peck, A.W., 1983. Effects of bupropion, nomifensine and
dexamphetamine on performance, subjective feelings, autonomic variables and
electroencephalogram in healthy volunteers. Br. J. Clin. Pharmacol. 15, 367–
374.
aney, M., Spealman, R., 2008. Controversies in translational research: drug self-
administration. Psychopharmacology (Berl) 199, 403–419.
arrigan, S.E., Downs, D.A., 1978. Self-administration of heroin, acetylmethadol,
morphine and methadone in rhesus monkeys. Life Sci. 22, 619–624.
arris, D.S., Baggott, M., Mendelson, J.H., Mendelson, J.E., Jones, R.T., 2002. Subjec-
tive and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA)
in humans. Psychopharmacology (Berl) 162, 396–405.
arris, R.T., Waters, W., McLendon, D., 1974. Evaluation of reinforcing capability
of delta-9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacologia 37,
23–29.
arrod, S.B., Dwoskin, L.P., Green, T.A., Gehrke, B.J., Bardo, M.T., 2003. Lobeline
does not serve as a reinforcer in rats. Psychopharmacology (Berl) 165, 397–
404.
ealth Canada, 2006. Guidance for Industry – Clinical Assessment of Abuse Liability
for Drugs with Central Nervous System Activity.
eil, S.H., Holmes,H.W., Bickel,W.K., Higgins, S.T., Badger, G.J., Laws,H.F., Faries, D.E.,
2002. Comparison of the subjective, physiological, and psychomotor effects of
atomoxetine andmethylphenidate in light drug users. Drug Alcohol Depend. 67,
149–156.
eishman, S.J., Henningﬁeld, J.E., 1991. Discriminative stimulus effects of
d-amphetamine, methylphenidate, and diazepam in humans. Psychopharma-
cology (Berl) 103, 436–442.
eishman, S.J., Snyder, F.R., Henningﬁeld, J.E., 1993. Performance, subjective, and
physiological effects of nicotine in non-smokers. Drug Alcohol Depend. 34,
11–18.
enningﬁeld, J.E., Cohen, C., Heishman, S.J., 1991. Drug self-administration methods
in abuse liability evaluation. Br. J. Addict. 86, 1571–1577.
enningﬁeld, J.E., Miyasato, K., Jasinski, D.R., 1985. Abuse liability and pharmaco-
dynamic characteristics of intravenous and inhaled nicotine. J. Pharmacol. Exp.
Ther. 234, 1–12.
enningﬁeld, J.E., Nemeth-Coslett, R., Katz, J.L., Goldberg, S.R., 1987. Intravenous
cocaine self-administration by human volunteers: second-order schedules of
reinforcement. NIDA Res. Monogr. 76, 266–273.
offmeister, F., 1977. Reinforcing properties of perphenazine, haloperidol and amit-
ryptiline in rhesus monkeys. J. Pharmacol. Exp. Ther. 200, 516–522.
offmeister, F., Schlichting, U.U., 1972. Reinforcing properties of some opiates
and opioids in rhesus monkeys with histories of cocaine and codeine self-
administration. Psychopharmacologia 23, 55–74.offmeister, F., Wuttke, W., 1973. Self-administration of acetylsalicylic acid and
combinations with codeine and caffeine in rhesus monkeys. J. Pharmacol. Exp.
Ther. 186, 266–275.
u, M., Crombag, H.S., Robinson, T.E., Becker, J.B., 2004. Biological basis of sex differ-
ences in the propensity to self-administer cocaine. Neuropsychopharmacology
29, 81–85.havioral Reviews 35 (2011) 912–938 935
Hursh, S.R., 1980. Economic concepts for the analysis of behavior. J. Exp. Anal. Behav.
34, 219–238.
ICHM3 (R2), 2010. CPMP/ICH/286/95. ICH Topic M3(R2). Note for guid-
ance on non-clinical safety studies for the conduct of human clini-
cal trials and marketing authorisation for pharmaceuticals. June 2009.
www.ema.europa.eu/pdfs/human/ich/028695en.pdf.
Jaffe, A.B., Sharpe, L.G., Jaffe, J.H., 1989. Rats self-administer sufentanil in aerosol
form. Psychopharmacology (Berl) 99, 289–293.
Jaffe, J.H., Bloor, R., Crome, I., Carr, M., Alam, F., Simmons, A., Meyer, R.E., 2004.
A postmarketing study of relative abuse liability of hypnotic sedative drugs.
Addiction 99 (2), 165–173.
Jaffe, J.H., Jaffe, F.K., 1989. Historical perspectives on the use of subjective effects
measures in assessing theabusepotential of drugs.NIDARes.Monogr. 92, 43–72.
Jasinski, D.R., 1977. Assessment of abuse potentiality of morphine-like drugs.
In: Martin, W.R. (Ed.), Drug Addiction 1. Morphine, Sedative-Hyponotic and
Alcohold Dependence. Handbook of Experimental Pharmacology. Springer, Hei-
delberg, pp. 197–258.
Jasinski, D.R., 2000. An evaluation of the abuse potential of modaﬁnil using
methylphenidate as a reference. J. Psychopharmacol. 14, 53–60.
Jasinski,D.R.,Henningﬁeld, J.E., 1989.Humanabuse liability assessmentbymeasure-
ment of subjective and physiological effects. NIDA Res. Monogr. 92, 73–100.
Jasinski, D.R., Kovacevic-Ristanovic, R., 2000. Evaluation of the abuse liability of
modaﬁnil and other drugs for excessive daytime sleepiness associated with
narcolepsy. Clin. Neuropharmacol. 23, 149–156.
Jasinski, D.R., Martin, W.R., Haertzen, C.A., 1967. The human pharmacology and
abuse potential of N-allylnoroxymorphone (naloxone). J. Pharmacol. Exp. Ther.
157, 420–426.
Jasinski, D.R., Nutt, J.G., Grifﬁth, J.D., 1974. Effects of diethylpropion and d-
amphetamine after subcutaneous and oral administration. Clin. Pharmacol.
Ther. 16, 645–652.
Jasinski, D.R., Preston, K.L., 1986. Evaluation of mixtures of morphine and d-
amphetamine for subjective and physiological effects. Drug Alcohol Depend.
17, 1–13.
Johanson, C.E., 1987. Benzodiazepine self-administration in rhesus monkeys: esta-
zolam, ﬂurazepam and lorazepam. Pharmacol. Biochem. Behav. 26, 521–526.
Johanson, C.E., 1990. The evaluation of the abuse liability of drugs. Drug Saf. 5 (Suppl.
1), 46–57.
Johanson, C.E., Balster, R.L., 1978. A summary of the results of a drug self-
administration study using substitution procedures in rhesus monkeys. Bull.
Narc. 30, 43–54.
Johanson, C.E., de Wit, H., 1989. The use of choice procedures for assessing the
reinforcing properties of drugs in humans. NIDA Res. Monogr. 92, 171–210.
Johanson, C.E., Schuster, C.R., 1981. A comparison of the behavioral effects of l- and
dl-cathinone and d-amphetamine. J. Pharmacol. Exp. Ther. 219, 355–362.
Johanson, C.E., Schuster, C.R., 1986. The effects of Ro 15-1788 on anxiolytic self-
administration in the rhesus monkey. Pharmacol. Biochem. Behav. 24, 855–
859.
Johanson, C.E., Uhlenhuth, E.H., 1981. Drug preference and mood in humans:
repeated assessment of d-amphetamine. Pharmacol. Biochem. Behav. 14,
159–163.
Johnson, B.A., Roache, J.D., Ait-Daoud, N., Wallace, C., Wells, L., Dawes, M., Wang, Y.,
2005. Effects of isradipine, a dihydropyridine-class calcium-channel antagonist,
on d-methamphetamine’s subjective and reinforcing effects. Int. J. Neuropsy-
chopharmacol. 8, 203–213.
Jonsson, C.O., Sjoberg, L., 1967. Studies in the psychological effects of a new drug
(diethylpropion). Time curves for ﬁve subjective variables. Scand. J. Psychol. 8,
39–46.
Jun, J.H., Thorndike, E.B., Schindler, C.W., 2004. Abuse liability and stimulant
properties of dextromethorphan and diphenhydramine combinations in rats.
Psychopharmacology (Berl) 172, 277–282.
Justinova, Z., Tanda, G., Redhi, G.H., Goldberg, S.R., 2003. Self-administration
of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psy-
chopharmacology (Berl) 169, 135–140.
Kanayama, G., Brower, K.J., Wood, R.I., Hudson, J.I., Pope Jr., H.G., 2010. Treatment
of anabolic-androgenic steroid dependence: emerging evidence and its impli-
cations. Drug Alcohol Depend. 109 (1–3), 6–13.
Kaplan, H.L., Busto, U.E., Baylon, G.J., Cheung, S.W., Otton, S.V., Somer, G., Sellers,
E.M., 1997. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to
hydromorphone does not importantly affect abuse liability. J. Pharmacol. Exp.
Ther. 281, 103–108.
Katz, J.L., 1990. Models of relative reinforcing efﬁcacy of drugs and their predictive
utility. Behav. Pharmacol. 1, 283–301.
Katz, J.L., Goldberg, S.R., 1988. Preclinical assessment of abuse liability of drugs.
Agents Actions 23, 18–26.
Kelly, T.H., Foltin, R.W., Mayr, M.T., Fischman, M.W., 1994. Effects of delta 9-
tetrahydrocannabinol and social context on marijuana self-administration by
humans. Pharmacol. Biochem. Behav. 49, 763–768.
Kim, D., Steinhart, B., 2010. Seizures induced by recreational abuse of bupropion
tablets via nasal insufﬂation. CJEM 12, 158–161.
Kim, I., Barnes, A.J., Oyler, J.M., Schepers, R., Joseph Jr., R.E., Cone, E.J., Lafko, D.,
Moolchan, E.T., Huestis, M.A., 2002. Plasma and oral ﬂuid pharmacokinet-
ics and pharmacodynamics after oral codeine administration. Clin. Chem. 48,
1486–1496.
Ko, M.C., Terner, J., Hursh, S., Woods, J.H., Winger, G., 2002. Relative reinforcing
effects of three opioids with different durations of action. J. Pharmacol. Exp.
Ther. 301, 698–704.
9 Biobe
K
K
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
M
M
M
M36 E.C. O’Connor et al. / Neuroscience and
osten, T.A., Miserendino, M.J., Haile, C.N., DeCaprio, J.L., Jatlow, P.I., Nestler, E.J.,
1997. Acquisition and maintenance of intravenous cocaine self-administration
in Lewis and Fischer inbred rat strains. Brain Res. 778, 418–429.
umor, K.M., Haertzen, C.A., Johnson, R.E., Kocher, T., Jasinski, D., 1986. Human psy-
chopharmacology of ketocyclazocine as compared with cyclazocine, morphine
and placebo. J. Pharmacol. Exp. Ther. 238, 960–968.
ahti, R.A., Collins, R.J., 1982. Opiate effects on plasma corticosteroids: relation-
ship to dysphoria and self-administration. Pharmacol. Biochem. Behav. 17, 107–
109.
amb, R.J., Grifﬁths, R.R., 1987. Self-injection of d,1-3,4-methylenedioxy-
methamphetamine (MDMA) in the baboon. Psychopharmacology (Berl)
91, 268–272.
amb,R.J., Grifﬁths, R.R., 1990. Self-administration inbaboonsand thediscriminative
stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine.
Psychopharmacology (Berl) 102, 183–190.
amb, R.J., Henningﬁeld, J.E., 1994. Human d-amphetamine drug discrimination:
methamphetamine and hydromorphone. J. Exp. Anal. Behav. 61, 169–180.
amb, R.J., Preston, K.L., Schindler, C.W., Meisch, R.A., Davis, F., Katz, J.L., Hen-
ningﬁeld, J.E., Goldberg, S.R., 1991. The reinforcing and subjective effects of
morphine in post-addicts: a dose-response study. J. Pharmacol. Exp. Ther. 259,
1165–1173.
ancaster, F.E., Spiegel, K.S., 1992. Sex differences in pattern of drinking. Alcohol 9,
415–420.
ange,W.R., Jasinski, D.R., 1986. The clinical pharmacology of pentazocine and tripe-
lennamine (T’s and Blues). Adv. Alcohol Subst. Abuse 5, 71–83.
au, C.E., Sun, L., 2002. The pharmacokinetic determinants of the frequency and
pattern of intravenous cocaine self-administration in rats by pharmacokinetic
modeling. Drug Metab. Dispos. 30, 254–261.
e Foll, B., Wertheim, C., Goldberg, S.R., 2007. High reinforcing efﬁcacy of nicotine
in non-human primates. PLoS ONE 2, e230.
ecca, D., Cacciapaglia, F., Valentini, V., Gronli, J., Spiga, S., Di Chiara, G., 2006. Prefer-
ential increase of extracellular dopamine in the rat nucleus accumbens shell as
compared to that in the core during acquisition andmaintenance of intravenous
nicotine self-administration. Psychopharmacology (Berl) 184, 435–446.
eri, F., Burns, L.H., 2005. Ultra-low-dose naltrexone reduces the rewarding potency
of oxycodone and relapse vulnerability in rats. Pharmacol. Biochem. Behav. 82,
252–262.
eSage, M.G., Stafford, D., Glowa, J.R., 2000. Abuse liability of the anesthetic propo-
fol: self-administration of propofol in rats under ﬁxed-ratio schedules of drug
delivery. Psychopharmacology (Berl) 153, 148–154.
eWitt, P.A., Ondo, W.G., Van Lunen, B., Bottini, P.B., 2009. Open-label study assess-
ment of safety and adverse effects of subcutaneous apomorphine injections in
treating “off” episodes in advanced Parkinson disease. Clin. Neuropharmacol.
32, 89–93.
icata, S.C., Rowlett, J.K., 2008. Abuse and dependence liability of benzodiazepine-
type drugs: GABA(A) receptor modulation and beyond. Pharmacol. Biochem.
Behav. 90, 74–89.
ile, J.A., 2006. Pharmacological determinants of the reinforcing effects of
psychostimulants: relation to agonist substitution treatment. Exp. Clin. Psy-
chopharmacol. 14, 20–33.
iu, X., Koren, A.O., Yee, S.K., Pechnick, R.N., Poland, R.E., London, E.D., 2003. Self-
administration of 5-iodo-A-85380, a beta2-selective nicotinic receptor ligand,
by operantly trained rats. Neuroreport 14, 1503–1505.
ukas, S.E., Grifﬁths, R.R., Brady, J.V., Wurster, R.M., 1984. Phencyclidine-analogue
self-injection by the baboon. Psychopharmacology (Berl) 83, 316–320.
ukas, S.E., Brady, J.V., Grifﬁths, R.R., 1986. Comparison of opioid self-injection and
disruption of schedule-controlled performance in the baboon. J. Pharmacol. Exp.
Ther. 238, 924–931.
ukas, S.E., Mendelson, J.H., Benedikt, R., 1995. Electroencephalographic correlates
of marihuana-induced euphoria. Drug Alcohol Depend. 37, 131–140.
ynch, W.J., 2006. Sex differences in vulnerability to drug self-administration. Exp.
Clin. Psychopharmacol. 14, 34–41.
ynch, W.J., Arizzi, M.N., Carroll, M.E., 2000. Effects of sex and the estrous cycle on
regulation of intravenously self-administered cocaine in rats. Psychopharma-
cology (Berl) 152, 132–139.
ynch, W.J., Carroll, M.E., 1999. Sex differences in the acquisition of intravenously
self-administered cocaine and heroin in rats. Psychopharmacology (Berl) 144,
77–82.
ynch, W.J., Taylor, J.R., 2004. Sex differences in the behavioral effects of 24-h/day
access to cocaine under a discrete trial procedure. Neuropsychopharmacology
29, 943–951.
yness, W.H., Smith, F.L., 1992. Inﬂuence of dopaminergic and serotonergic neu-
rons on intravenous ethanol self-administration in the rat. Pharmacol. Biochem.
Behav. 42, 187–192.
adden, C., Singer, G., Oei, T.P., 1979. The involvement of interoceptive factors in
the maintenance of heroin-seeking behavior. Pharmacol. Biochem. Behav. 11,
445–448.
aldonado, R., 2002. Study of cannabinoid dependence in animals. Pharmacol. Ther.
95, 153–164.
ansbach, R.S., Feltner, D.E., Gold, L.H., Schnoll, S.H., 2003. Incorporating the assess-
ment of abuse liability into the drug discovery and development process. Drug
Alcohol Depend. 70, S73–S85.
ansbach, R.S., Nicholson, K.L., Martin, B.R., Balster, R.L., 1994. Failure of
Delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-
administration under a ﬁxed-interval schedule in rhesus monkeys. Behav.
Pharmacol. 5, 219–225.havioral Reviews 35 (2011) 912–938
Markert, L.E., Roberts, D.C., 1991. 3,4-Methylenedioxyamphetamine (MDA) self-
administration and neurotoxicity. Pharmacol. Biochem. Behav. 39, 569–574.
Marquis, K.L., Moreton, J.E., 1987. Animal models of intravenous phencyclinoid self-
administration. Pharmacol. Biochem. Behav. 27 (2), 385–389, 27, 385–389.
Marquis, K.L., Webb, M.G., Moreton, J.E., 1989. Effects of ﬁxed ratio size and dose
on phencyclidine self-administration by rats. Psychopharmacology (Berl) 97,
179–182.
Martin, T.J., Kim, S.A., Harris, L.S., Smith, J.E., 1997. Potent reinforcing effects of
dihydroetorphine in rats. Eur. J. Pharmacol. 324, 141–145.
Martin, W.R., Sloan, J.W., Sapira, J.D., Jasinski, D.R., 1971. Physiologic, subjective,
and behavioral effects of amphetamine, methamphetamine, ephedrine, phen-
metrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12, 245–258.
Martinez, D., Broft, A., Foltin, R.W., Slifstein, M., Hwang, D.R., Huang, Y., Perez,
A., Frankle, W.G., Cooper, T., Kleber, H.D., Fischman, M.W., Laruelle, M., 2004.
Cocaine dependence and d2 receptor availability in the functional subdivisions
of the striatum: relationship with cocaine-seeking behavior. Neuropsychophar-
macology 29, 1190–1202.
Marvin Davis, W., Smith, S.G., Werner, T.E., Braude, M.C., 1977. Intragastric self-
administration of hallucinogens in the rat. In: Federation of American Societies
for Experimental Biology: 61st Annual Meeting, Chicago, IL, USA.
McColl, S.L., Burstein, A.H., Reeves, K.R., Billing Jr., C.B., Stolar, M., Sellers, E.M., 2008.
Human abuse liability of the smoking cessation drug varenicline in smokers and
nonsmokers. Clin. Pharmacol. Ther. 83, 607–614.
McLeod, D.R., Grifﬁths, R.R., 1983. Human progressive-ratio performance: mainte-
nance by pentobarbital. Psychopharmacology (Berl) 79, 4–9.
Meisch, R.A., 1995.Oral self-administration of etonitazene in rhesusmonkeys: use of
a fading procedure to establish etonitazene as a reinforcer. Pharmacol. Biochem.
Behav. 50, 571–580.
Meisch, R.A., Lemaire, G.A., 1990. Reinforcing effects of a pentobarbital-ethanol com-
bination relative to each drug alone. Pharmacol. Biochem. Behav. 35, 443–450.
Mello, N.K., Lukas, S.E., Bree, M.P., Mendelson, J.H., 1988. Progressive ratio per-
formance maintained by buprenorphine, heroin and methadone in Macaque
monkeys. Drug Alcohol Depend. 21, 81–97.
Mello, N.K., Mendelson, J.H., Sholar, M.B., Jaszyna-Gasior, M., Goletiani, N., Siegel,
A.J., 2005. Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced
changes in subjective and cardiovascular responses in men. Neuropsychophar-
macology 30, 618–632.
Meyer, A.C., Rahman, S., Charnigo, R.J., Dwoskin, L.P., Crabbe, J.C., Bardo, M.T., 2010.
Genetics of novelty seeking, amphetamine self-administration and reinstate-
ment using inbred rats. Genes Brain Behav. 9 (7), 790–798.
Miller, L., Grifﬁth, J., 1983. A comparison of bupropion, dextroamphetamine, and
placebo in mixed-substance abusers. Psychopharmacology (Berl) 80, 199–205.
Mintzer, M.Z., Guarino, J., Kirk, T., Roache, J.D., Grifﬁths, R.R., 1997. Ethanol and
pentobarbital: comparison of behavioral and subjective effects in sedative drug
abusers. Exp. Clin. Psychopharmacol. 5, 203–215.
Moreton, J., Meisch, E.R., Stark, A., Thompson, L.T., 1977. Ketamine self-
administration by the rhesus monkey. J. Pharmacol. Exp. Ther. 203, 303–309.
Moreton, J.E., Roehrs, T., Khazan, N., 1976. Drug self-administration and sleep-awake
activity in rats dependent on morphine, methadone, or l-alpha-acetylmethadol.
Psychopharmacology (Berl) 47, 237–241.
Morgan, C.J., Mofeez, A., Brandner, B., Bromley, L., Curran, H.V., 2004. Ketamine
impairs response inhibition and is positively reinforcing in healthy volunteers:
a dose-response study. Psychopharmacology (Berl) 172, 298–308.
Mumford, G.K., Silverman, K., Grifﬁths, R.R., 1996. Reinforcing, subjective, and per-
formance effects of lorazepam and diphenhydramine in humans. Exp. Clin.
Psychopharmacol. 4, 421–430.
Munzar, P., Baumann, M.H., Shoaib, M., Goldberg, S.R., 1999. Effects of dopamine
and serotonin-releasing agents on methamphetamine discrimination and self-
administration in rats. Psychopharmacology (Berl) 141, 287–296.
Munzar, P., Yasar, S., Redhi, G.H., Justinova, Z., Goldberg, S.R., 2001. High rates
of midazolam self-administration in squirrel monkeys. Behav. Pharmacol. 12,
257–265.
Mutschler, J., Koopmann, A., Grosshans, M., Hermann, D., Mann, K., Kiefer, F., 2010.
Dextromethorphan withdrawal and dependence syndrome. Dtsch. Arztebl. Int.
107, 537–540.
Naranjo, C., Shulgin, A.T., Sargent, T., 1967. Evaluation of 3,4-methylenedi-
oxyamphetamine (MDA) as an adjunct to psychotherapy. Med. Pharmacol. Exp.
Int. J. Exp. Med. 17, 359–364.
Naruse, T., Asami, T., 1990. Cross-dependence on ethanol and pentobarbital in rats
reinforced on diazepam. Arch. Int. Pharmacodyn. Ther. 304, 147–162.
Negus, S.S., 2003. Rapid assessment of choice between cocaine and food in rhe-
sus monkeys: effects of environmental manipulations and treatment with
d-amphetamine and ﬂupenthixol. Neuropsychopharmacology 28, 919–931.
Newman, J.L., Thorne, J.J., Batulis, D.K., Carroll, M.E., 2006. Effects of menstrual cycle
phase on the reinforcing effects of phencyclidine (PCP) in rhesusmonkeys. Phar-
macol. Biochem. Behav. 85, 584–591.
Nicholson, K.L., Balster, R.L., 2001. GHB: a new and novel drug of abuse. Drug Alcohol
Depend. 63, 1–22.
Nicholson, K.L., Hayes, B.A., Balster, R.L., 1999. Evaluation of the reinforc-
ing properties and phencyclidine-like discriminative stimulus effects of
dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychophar-
macology (Berl) 146, 49–59.
Nielsen, J.A., Duda, N.J., Mokler, D.J., Moore, K.E., 1984. Self-administration of
central stimulants by rats: a comparison of the effects of d-amphetamine,
methylphenidate and McNeil 4612. Pharmacol. Biochem. Behav. 20, 227–
232.
Biobe
N
N
O
O
O
O
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
R
R
R
R
R
R
R
R
R
RE.C. O’Connor et al. / Neuroscience and
ishida, N., Hasegawa, Y., Chiba, S., Wakimasu, M., Fujino, M., 1989. Reinforcing
effects of the enkephalin analogs, EK-209 and EK-399, in rats. Eur. J. Pharmacol.
166, 453–458.
utt, D., King, L.A., Saulsbury, W., Blakemore, C., 2007. Development of a rational
scale to assess the harm of drugs of potential misuse. Lancet 369, 1047–1053.
’Connor, E.C., Mead, A.N., 2010. Tramadol acts as a weak Reinforcer in the Rat
Self-Administration Model, consistent with its low abuse liability in humans.
Pharmacol. Biochem. Behav., doi:10.1016/j.pbb.2010.05.018.
’Connor, E.C., Parker, D., Rollema, H., Mead, A.N., 2010. The alpha4beta2 nicotinic
acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-
administration following repeated dosing and reinstatement of nicotine seeking
in rats. Psychopharmacology (Berl) 208, 365–376.
ei, T.P., 1983. Effects of body weight reduction and food deprivation on cocaine
self-administration. Pharmacol. Biochem. Behav. 19, 453–455.
ittinen, H., Rameis, H., Saria, A., Zernig, G., 2001. Lack of reinforcing effect of the
benzodiazepineand tricyclic antidepressant combinationofdiazepamanddoth-
iepin. Pharmacology 62, 124–128.
akarinen, E.D.,Williams, K.L.,Woods, J.H., 1999. Food restriction and sexdifferences
on concurrent, oral ethanol and water reinforcers in juvenile rhesus monkeys.
Alcohol 17, 35–40.
anagis, G., Vlachou, S., Nomikos, G.G., 2008. Behavioral pharmacology of cannabi-
noids with a focus on preclinical models for studying reinforcing and
dependence-producing properties. Curr. Drug Abuse Rev. 1, 350–374.
anksepp, J., Knutson, B., Burgdorf, J., 2002. The role of brain emotional systems
in addictions: a neuro-evolutionary perspective and new ‘self-report’ animal
model. Addiction 97, 459–469.
anlilio, L.V., Goldberg, S.R., 2007. Self-administration of drugs in animals and
humans as a model and an investigative tool. Addiction (Abingdon, England)
102, 1863–1870.
anlilio, L.V., Schindler, C.W., 2000. Self-administration of remifentanil, an ultra-
short acting opioid, under continuous and progressive-ratio schedules of
reinforcement in rats. Psychopharmacology (Berl) 150, 61–66.
apasava, M., Singer, G., Papasava, C., 1986. Food deprivation fails to potentiate
intravenous self-administration of fenﬂuramine in naive rats. Appetite 7, 55–61.
apasava, M., Singer, G., Papasava, C.L., 1985. Phentermine self-administration in
naive free-feeding and food-deprived rats: a dose response study. Psychophar-
macology (Berl) 85, 410–413.
ark, K.S., Hong, J.T., Ryu, S.R., Kim, H.J., Lee, J.K., Bae, Y.C., Kim, P.Y., Lee, S.H., 2000.
Evaluation of abuse liability of ephedrine using rats. In: 30th Annual Meeting of
the Society of Neuroscience, November 04–09, 2000, New Orleans, LA, USA.
ickens, R., Harris, W.C., 1968. Self-administration of d-amphetamine by rats. Psy-
chopharmacologia 12, 158–163.
ickens, R., Muchow, D., DeNoble, V., 1981. Methohexital-reinforced responding in
rats: effects of ﬁxed ratio size and injection dose. J. Pharmacol. Exp. Ther. 216,
205–209.
ilotto, R., Singer, G., Overstreet, D., 1984. Self-injection of diazepam in naive rats:
effects of dose, schedule and blockade of different receptors. Psychopharmacol-
ogy (Berl) 84, 174–177.
reston,K.L., Jasinski,D.R., 1991.Abuse liability studies of opioid agonist-antagonists
in humans. Drug Alcohol Depend. 28, 49–82.
reston, K.L., Jasinski, D.R., Testa, M., 1991. Abuse potential and pharmacological
comparison of tramadol and morphine. Drug Alcohol Depend. 27, 7–17.
reston, K.L., Sullivan, J.T., Strain, E.C., Bigelow, G.E., 1992a. Effects of cocaine alone
and in combinationwith bromocriptine in human cocaine abusers. J. Pharmacol.
Exp. Ther. 262, 279–291.
reston, K.L., Wolf, B., Guarino, J.J., Grifﬁths, R.R., 1992b. Subjective and behav-
ioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation
of abuse liability. J. Pharmacol. Exp. Ther. 262, 707–720.
analdi, R., Woolverton, W.L., 2002. Self-administration of cocaine: scopolamine
combinations by rhesus monkeys. Psychopharmacology (Berl) 161, 442–448.
atzenboeck, E., Saria, A., Kriechbaum, N., Zernig, G., 2001. Reinforcing effects of
MDMA (“ecstasy”) in drug-naive and cocaine-trained rats. Pharmacology 62,
138–144.
ichardson, J.S., 1970. The self-injection of amobarbital by rats during non-reward.
Int. J. Addict. 5, 739–746.
ichardson, N.R., Roberts, D.C., 1996. Progressive ratio schedules in drug self-
administration studies in rats: a method to evaluate reinforcing efﬁcacy. J.
Neurosci. Methods 66, 1–11.
oache, J.D., Grifﬁths, R.R., 1989. Diazepam and triazolam self-administration in
sedative abusers: concordance of subject ratings, performance and drug self-
administration. Psychopharmacology (Berl) 99, 309–315.
ocha, B., Ward, A.A., Egilmez, S., Lytle, Y.D., Emmett-Oglesby, A.M.W., 1996. Toler-
ance to the discriminative stimulus and reinforcing effects of ketamine. Behav.
Pharmacol. 7, 160–168.
ollema, H., Chambers, L.K., Coe, J.W., Glowa, J., Hurst, R.S., Lebel, L.A., Lu, Y., Mans-
bach, R.S.,Mather, R.J., Rovetti, C.C., Sands, S.B., Schaeffer, E., Schulz,D.W., Tingley
3rd, F.D., Williams, K.E., 2007. Pharmacological proﬁle of the alpha(4)beta(2)
nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking
cessation aid. Neuropharmacology 52 (3), 985–994.
omanelli, F., Smith, K.M., 2009. Dextromethorphan abuse: clinical effects andman-
agement. J. Am. Pharm. Assoc. 49 (2), e20–e27.
oth, M.E., Cosgrove, K.P., Carroll, M.E., 2004. Sex differences in the vulnerability to
drugabuse: a reviewofpreclinical studies.Neurosci. Biobehav. Rev. 28, 533–546.
owlett, J.K., 2000. A labor-supply analysis of cocaine self-administration under
progressive-ratio schedules: antecedents, methodologies, and perspectives.
Psychopharmacology (Berl) 153, 1–16.havioral Reviews 35 (2011) 912–938 937
Rowlett, J.K., Wilcox, K.M., Woolverton, W.L., 1998. Self-administration of cocaine-
heroin combinations by rhesus monkeys: antagonism by naltrexone. J.
Pharmacol. Exp. Ther. 286, 61–69.
Sanchis-Segura, C., Spanagel, R., 2006. Behavioural assessment of drug reinforce-
ment and addictive features in rodents: an overview. Addict. Biol. 11, 2–38.
Sannerud, C.A., Kaminski, B.J., Grifﬁths, R.R., 1995. Maintenance of H1 antagonists
self-injection in baboons. Exp. Clin. Psychopharmacol. 3, 26–32.
Sannerud, C.A., Prada, J., Goldberg, D.M., Goldberg, S.R., 1994. The effects of sertra-
line on nicotine self-administration and food-maintained responding in squirrel
monkeys. Eur. J. Pharmacol. 271, 461–469.
Schenk, S., Gittings, D., Johnstone, M., Daniela, E., 2003. Development, maintenance
and temporal pattern of self-administration maintained by ecstasy (MDMA) in
rats. Psychopharmacology (Berl) 169, 21–27.
Schlaepfer, T.E., Strain, E.C., Greenberg, B.D., Preston, K.L., Lancaster, E., Bigelow, G.E.,
Barta, P.E., Pearlson, G.D., 1998. Site of opioid action in the human brain: mu and
kappa agonists’ subjective and cerebral blood ﬂow effects. Am. J. Psychiatry 155,
470–473.
Schuster, C.R., Thompson, T., 1969. Self administrationof andbehavioral dependence
on drugs. Annu. Rev. Pharmacol. 9, 483–502.
Sekita, K., Ochiai, T., Ohno, K., Murakami, O., Wakasa, Y., Uzawa, K., Furuya, T.,
Kurokawa, Y., 1992. Studies on reinforcing effects of methylephedrine, caffeine
and theirmixturewith intravenous-self administration in rhesusmonkeys. Eisei
Shikenjo Hokoku 110, 15–22.
Shearman, G.T., Hynes, M., Lal, H., 1981. Self-administration of clonidine by the rat.
Prog. Clin. Biol. Res. 71, 259–276.
Shoaib, M., 2006. Effects of isoarecolone, a nicotinic receptor agonist in rodent mod-
els of nicotine dependence. Psychopharmacology (Berl) 188, 252–257.
Singh, R.K., Jain, R., Ray, R., Gupta, Y.K., 2001. Abuse liability of diazepam through
different routes. Indian J. Physiol. Pharmacol. 45, 181–190.
Slifer, B.L., Balster, R.L., 1983. Reinforcing properties of stereoisomers of the puta-
tive sigma agonists N-allylnormetazocine and cyclazocine in rhesus monkeys. J.
Pharmacol. Exp. Ther. 225, 522–528.
Slifer, B.L., Balster, R.L., 1985. Intravenous self-administration of nicotine: with and
without schedule-induction. Pharmacol. Biochem. Behav. 22, 61–69.
Soria, R., Stapleton, J.M., Gilson, S.F., Sampson-Cone, A., Henningﬁeld, J.E., London,
E.D., 1996. Subjectiveandcardiovascular effectsof intravenousnicotine in smok-
ers and non-smokers. Psychopharmacology (Berl) 128, 221–226.
Spillane, J., McAllister, W.B., 2003. Keeping the lid on: a century of drug regulation
and control. Drug Alcohol Depend. 70, S5–S12.
Spyraki, C., Fibiger, H.C., 1981. Intravenous self-administration of nomifensine in
rats: implications for abuse potential in humans. Science 212, 1167–1168.
Stafford,D., LeSage,M.G.,Glowa, J.R., 1998. Progressive-ratio schedulesofdrugdeliv-
ery in the analysis of drug self-administration: a review. Psychopharmacology
(Berl) 139, 169–184.
Stathis, M., Scheffel, U., Lever, S.Z., Boja, J.W., Carroll, F.I., Kuhar, M.J., 1995. Rate of
binding of various inhibitors at the dopamine transporter in vivo. Psychophar-
macology (Berl) 119, 376–384.
Steinfels, G.F., Young, G.A., Khazan, N., 1982. Self-administration of nalbuphine,
butorphanol and pentazocine by morphine post-addict rats. Pharmacol.
Biochem. Behav. 16, 167–171.
Stephens, D.N., Duka, T., Crombag, H.S., Cunningham, C.L., Heilig, M., Crabbe, J.C.,
2010. Reward sensitivity: issues of measurement, and achieving consilience
between human and animal phenotypes. Addict. Biol. 15, 145–168.
Stern, K.N., Chait, L.D., Johanson, C.E., 1989. Reinforcing and subjective effects of oral
tripelennamine in normal human volunteers. Behav. Pharmacol. 1, 161–167.
Stewart, B.S., Lemaire, G.A., Roache, J.D., Meisch, R.A., 1994. Establishing benzodi-
azepines as oral reinforcers: midazolam and diazepam self-administration in
rhesus monkeys. J. Pharmacol. Exp. Ther. 271, 200–211.
Stewart, R.B., Grabowski, J., Wang, N.S., Meisch, R.A., 1996. Orally delivered
methadone as a reinforcer in rhesus monkeys. Psychopharmacology (Berl) 123,
111–118.
Sullivan, J.T., Jasinski, D.R., Johnson, R.E., 1993. Single-dose pharmacodynamics of
diazepam and pentobarbital in substance abusers. Clin. Pharmacol. Ther. 54,
645–653.
Suzuki, T., George, F.R., Meisch, R.A., 1992. Etonitazene delivered orally serves as a
reinforcer for Lewis but not Fischer 344 rats. Pharmacol. Biochem. Behav. 42,
579–586.
Sziraki, Lipovac, M.N., Hashim, A., Sershen, H., Allen, D., Cooper, T., Czobor, P., Lajtha,
A., 2001. Differences in nicotine-induced dopamine release and nicotine phar-
macokinetics betweenLewis andFischer 344 rats.Neurochem.Res. 26, 609–617.
Szostak, C., Finlay, J.M., Fibiger, H.C., 1987. Intravenous self-administration of the
short-acting benzodiazepine midazolam in the rat. Neuropharmacology 26,
1673–1676.
Taeuber, K., Zapf, R., Rupp, W., Badian, M., 1979. Pharmacodynamic comparison of
the acute effects of nomifensine, amphetamine and placebo in healthy volun-
teers. Int. J. Clin. Pharmacol. Biopharm. 17, 32–37.
Takahashi, R.N., Singer, G., 1979. Self-administration of delta 9-
tetrahydrocannabinol by rats. Pharmacol. Biochem. Behav. 11, 737–740.
Takahashi, R.N., Singer, G., 1980. Effects of body weight levels on cannabis self-
injection. Pharmacol. Biochem. Behav. 13, 877–881.Tanda, G., Goldberg, S.R., 2003. Cannabinoids: reward, dependence, and underlying
neurochemicalmechanisms-a review of recent preclinical data. Psychopharma-
cology (Berl) 169, 115–134.
Tanda, G., Munzar, P., Goldberg, S.R., 2000. Self-administration behavior is main-
tained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat.
Neurosci. 3, 1073–1074.
9 Biobe
T
T
T
T
T
T
U
U
v
V
V
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W38 E.C. O’Connor et al. / Neuroscience and
ella, S.R., Ladenheim, B., Cadet, J.L., 1997. Differential regulation of dopamine
transporter after chronic self-administration of bupropion and nomifensine. J.
Pharmacol. Exp. Ther. 281, 508–513.
essari, M., Valerio, E., Chiamulera, C., Beardsley, P.M., 1995. Nicotine reinforcement
in ratswith histories of cocaine self-administration. Psychopharmacology (Berl)
121, 282–283.
homas,A.,Nallur,D.G., Jones,N.,Deslandes, P.N., 2009.Diphenhydramineabuseand
detoxiﬁcation: a brief review and case report. J. Psychopharmacol. 23, 101–105.
omkins,D.M.,Otton, S.V., Joharchi,N., Li,N.Y., Balster, R.F., Tyndale,R.F., Sellers, E.M.,
1997. Effectof cytochromeP4502D1 inhibitiononhydrocodonemetabolismand
its behavioral consequences in rats. J. Pharmacol. Exp. Ther. 280, 1374–1382.
sibulsky, V.L., Norman, A.B., 2005. Real time computation of in vivo drug levels
during drug self-administration experiments. Brain Res. Brain Res. Protoc. 15,
38–45.
zschentke, T.M., 1998. Measuring reward with the conditioned place preference
paradigm: a comprehensive review of drug effects, recent progress and new
issues. Prog. Neurobiol. 56, 613–672.
K Government. Animals (Scientiﬁc Procedures) Act 1986. London: HMSO; 1986.
http://www.archive.ofﬁcial-documents.co.uk/document/hoc/321/321-xa.htm.
.S. Department of Justice, D.E.A., 2009. List of Scheduling Actions, Controlled Sub-
stances, Regulated Chemicals.
an Ree, J.M., Slangen, J.L., de Wied, D., 1978. Intravenous self-administration of
drugs in rats. J. Pharmacol. Exp. Ther. 204, 547–557.
anover, K.E., Wenger, G.R., Woolverton, W.L., 1989. Self-administration of the iso-
mers of pentobarbital and secobarbital by rhesusmonkeys. Pharmacol. Biochem.
Behav. 34, 669–671.
ivero, L.E., Anderson, P.O., Clark, R.F., 1998. A close look at fenﬂuramine anddexfen-
ﬂuramine. J. Emerg. Med. 16, 197–205.
achtel, S.R., Ortengren, A., de Wit, H., 2002. The effects of acute haloperidol or
risperidone on subjective responses to methamphetamine in healthy volun-
teers. Drug Alcohol Depend. 68, 23–33.
alker, D.J., Zacny, J.P., 1998. Subjective, psychomotor, and analgesic effects of oral
codeine and morphine in healthy volunteers. Psychopharmacology (Berl) 140,
191–201.
alker, D.J., Zacny, J.P., 1999. Subjective, psychomotor, and physiological effects of
cumulative doses of opioidmu agonists in healthy volunteers. J. Pharmacol. Exp.
Ther. 289, 1454–1464.
alsh, S.L., June, H.L., Schuh, K.J., Preston, K.L., Bigelow, G.E., Stitzer, M.L., 1995.
Effects of buprenorphine and methadone in methadone-maintained subjects.
Psychopharmacology (Berl) 119, 268–276.
alsh, S.L., Strain, E.C., Abreu, M.E., Bigelow, G.E., 2001. Enadoline, a selective kappa
opioid agonist: comparison with butorphanol and hydromorphone in humans.
Psychopharmacology (Berl) 157, 151–162.
ang, Z., Woolverton, W.L., 2007. Estimating the relative reinforcing strength
of (+/−)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in
rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology
(Berl) 189, 483–488.
ard, A.S., Li, D.H., Luedtke, R.R., Emmett-Oglesby,M.W., 1996. Variations in cocaine
self-administration by inbred rat strains under a progressive-ratio schedule.
Psychopharmacology (Berl) 127, 204–212.
ard, S.J., Morgan, D., Roberts, D.C., 2005. Comparison of the reinforcing effects of
cocaine and cocaine/heroin combinations under progressive ratio and choice
schedules in rats. Neuropsychopharmacology 30, 286–295.
eed,M.R.,Woolverton,W.L., 1995. The reinforcing effects of dopamineD1 receptor
agonists in rhesus monkeys. J. Pharmacol. Exp. Ther. 275, 1367–1374.
eeks, J.R., 1962. Experimental morphine addiction: method for automatic intra-
venous injections in unrestrained rats. Science 138, 143–144.
eerts, E.M., Ator, N.A., Grifﬁths, R.R., 1999. Comparison of the intravenous rein-
forcing effects of propofol and methohexital in baboons. Drug Alcohol Depend.
57, 51–60.
eerts, E.M., Fantegrossi, W.E., Goodwin, A.K., 2007. The value of nonhuman pri-
mates in drug abuse research. Exp. Clin. Psychopharmacol. 15, 309–327.
eerts, E.M., Grifﬁths, R.R., 1999. Evaluation of the intravenous reinforcing effects
of clonidine in baboons. Drug Alcohol Depend. 53, 207–214.
ellman, P.J., Shelton, K., Schenk, S., 1989. Self-administration of phenyl-
propanolamine (PPA) by rats previously trained to self-administer
amphetamine. Pharmacol. Biochem. Behav. 34, 187–191.
erner, T.E., Smith, S.G., Davis, W.M., 1976. A dose-response comparison
between methadone and morphine self-administration. Psychopharmacologia
47, 209–211.
illiams, K.L., Broadbear, J.H., Woods, J.H., 2004. Noncontingent and response-
contingent intravenous ethanol attenuates the effect of naltrexone on
hypothalamic-pituitary-adrenal activity in rhesus monkeys. Alcohol Clin. Exp.
Res. 28, 566–571.
ilson, A.W., Neill, J.C., Costall, B., 1997. Strain differences in ethanol preference
and reinforced behaviour: a comparison of two-bottle choice and operant self-
administration paradigms. Behav. Pharmacol. 8, 37–46.
ilson, C., Canning, P., Caravati, E.M., 2010. The abuse potential of propofol. Clin.
Toxicol. (Phila.) 48, 165–170.
inger, G., Stitzer, M.L., Woods, J.H., 1975. Barbiturate-reinforced responding in
rhesus monkeys: comparisons of drugs with different durations of action. J.
Pharmacol. Exp. Ther. 195, 505–514.havioral Reviews 35 (2011) 912–938
Wise, R.A., Murray, A., Bozarth, M.A., 1990. Bromocriptine self-administration
and bromocriptine-reinstatement of cocaine-trained and heroin-trained lever
pressing in rats. Psychopharmacology (Berl) 100, 355–360.
Wolf, B., Guarino, J.J., Preston, K.L., Grifﬁths, R.R., 1989. Abuse liability of diphenhy-
dramine in sedative abusers. NIDA Res. Monogr. 95, 486–487.
Wood, R.I., Johnson, L.R., Chu, L., Schad, C., Self, D.W., 2004. Testosterone reinforce-
ment: intravenous and intracerebroventricular self-administration in male rats
and hamsters. Psychopharmacology (Berl) 171, 298–305.
Woods, J.H., Smith, C.B., Medzihradsky, F., Swain, H.H., 1979. Preclinical Testing of
New Analgesic Drugs. Raven Press, New York.
Woods, J.H., Young, A.M., Medzihradsky, F., Smith, C.B., Aceto, M.D., Harris, L.S.,
Jacobson, A.E., 1983. Zomepirac: preclinical narcotic abuse liability evaluation.
Arzneimittelforschung 33, 218–222.
Woolverton, W.L., Goldberg, L.I., Ginos, J.Z., 1984. Intravenous self-administration
of dopamine receptor agonists by rhesus monkeys. J. Pharmacol. Exp. Ther. 230,
678–683.
Woolverton, W.L., Johanson, C.E., de la Garza, R., Ellis, S., Seiden, L.S., Schuster,
C.R., 1986. Behavioral and neurochemical evaluation of phenylpropanolamine.
J. Pharmacol. Exp. Ther. 237, 926–930.
Woolverton, W.L., Nader, M.A., 1990. Experimental Evaluation of the Reinforcing
Effects of Drugs, Modern Methods in Pharmacology. Wiley-Liss, Inc, pp. 165–
192.
Woolverton,W.L., Rowlett, J.K.,Winger, G.,Woods, J.H., Gerak, L.R., France, C.P., 1999.
Evaluation of the reinforcing and discriminative stimulus effects of gamma-
hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend. 54, 137–143.
Woolverton, W.L., Wessinger, W.D., Balster, R.L., 1982. Reinforcing properties of
clonidine in rhesus monkeys. Psychopharmacology (Berl) 77, 17–23.
Wu, W.R., Zheng, J.W., Li, F.Y., Li, Y., 1998. Immunosuppressive effects of intra-
venous self administration of dihydroetorphine on lymphocyte functions in rats.
Zhongguo Yao Li Xue Bao 19, 387–390.
Yanagita, T., 1978. Drug dependence potential of 1-(m-methoxyphenyl)-2-
dimethylaminomethyl)-cyclohexan-1-ol hydrochloride (tramadol) tested in
monkeys. Arzneimittelforschung 28, 158–163.
Yanagita, T., Nagaoki, O., Takahashi, S., 1975a. Drug dependence liability of penta-
zocine evaluated in Rhesus monkeys. CIEA Preclin. Rpt. 1, 51–57.
Yanagita, T., Takahashi, S., Oinuma, N., 1975b. Drug dependence liaibility test on
AT-17 in the Rhesus Monkey. CIEA Preclin. Rpt. 1, 35–41.
Yanigita, T., Takahashi, S., 1973. Dependance liability of several sedative hypnotic
agents evaluated in monkeys. J. Pharmacol. Expt. Ther. 185, 307–316.
Yokel, R.A., Pickens, R., 1973. Self-administration of optical isomers of amphetamine
and methylamphetamine by rats. J. Pharmacol. Exp. Ther. 187, 27–33.
Yokel, R.A., Wise, R.A., 1978. Amphetamine-type reinforcement by dopaminergic
agonists in the rat. Psychopharmacology (Berl) 58, 289–296.
Yoshimura, K., Horiuchi, M., Inoue, Y., Yamamoto, K., 1984. [Pharmacological
studies on drug dependence, (III): intravenous self-administration of some CNS-
affecting drugs and a new sleep-inducer, 1H-1, 2, 4-triazolyl benzophenone
derivative (450191-S), in rats]. Nippon Yakurigaku Zasshi 83, 39–67.
Young, A.M., Stephens, K.R., Hein, D.W., Woods, J.H., 1984. Reinforcing and discrim-
inative stimulus properties of mixed agonist-antagonist opioids. J. Pharmacol.
Exp. Ther. 229, 118–126.
Young, A.M., Woods, J.H., 1981. Maintenance of behavior by ketamine and related
compounds in rhesus monkeys with different self-administration histories. J.
Pharmacol. Exp. Ther. 218, 720–727.
Young, G.A., Khazan, N., 1983. Self-administration of ketocyclazocine and ethylke-
tocyclazocine by the rat. Pharmacol. Biochem. Behav. 19, 711–713.
Young, G.A., Steinfels, G.F., Khazan, N., 1979. Spontaneous vs. naloxone-induced
abstinence in dependent rats self-administering L-alpha-acetylmethadol
(LAAM) or morphine. Pharmacol. Biochem. Behav. 10, 585–589.
Zacny, J.P., 2005. Proﬁling the subjective, psychomotor, and physiological effects of
tramadol in recreational drug users. Drug Alcohol Depend. 80, 273–278.
Zacny, J.P., Conley, K., Marks, S., 1997. Comparing the subjective, psychomotor and
physiological effects of intravenous nalbuphine and morphine in healthy vol-
unteers. J. Pharmacol. Exp. Ther. 280, 1159–1169.
Zacny, J.P., Gutierrez, S., 2003. Characterizing the subjective, psychomotor, and
physiological effects of oral oxycodone in non-drug-abusing volunteers. Psy-
chopharmacology (Berl) 170, 242–254.
Zacny, J.P., Hill, J.L., Black, M.L., Sadeghi, P., 1998. Comparing the subjective, psy-
chomotor and physiological effects of intravenous pentazocine and morphine
in normal volunteers. J. Pharmacol. Exp. Ther. 286, 1197–1207.
Zacny, J.P., Lichtor, J.L., Klafta, J.M., Alessi, R., Apfelbaum, J.L., 1996. The effects of
transnasal butorphanol on mood and psychomotor functioning in healthy vol-
unteers. Anesth. Analg. 82, 931–935.
Zacny, J.P., Lichtor, J.L., Zaragoza, J.G., Coalson, D.W., Uitvlugt, A.M., Flemming, D.C.,
Binstock, W.B., Cutter, T., Apfelbaum, J.L., 1993. Assessing the behavioral effects
and abuse potential of propofol bolus injections in healthy volunteers. Drug
Alcohol Depend. 32, 45–57.Zawertailo, L.A., Busto, U., Kaplan, H.L., Sellers, E.M., 1995. Comparative abuse lia-
bility of sertraline, alprazolam, and dextroamphetamine in humans. J. Clin.
Psychopharmacol. 15, 117–124.
Ziaee, V., Akbari, H.E., Hoshmand, A., Amini, H., Kebriaeizadeh, A., Saman, K., 2005.
Side effects of dextromethorphan abuse, a case series. Addict. Behav. 30 (8),
1607–1613, 1607–13, 30.
